APPENDIX:

Behavioral and Clinical Characteristics of People Living with Diagnosed HIV in California 2015-2019

California Department of Public Health
Center for Infectious Diseases
Office of AIDS
Medical Monitoring Project

March 2022

List of Appendix Tables

List of Appendix Tables

This page is left intentionally blank.

Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	% [a] (95% CI) [b]	% [a] (95% CI) [b]	% [a] (95% CI) [b]	% [a] (95% CI) [b]	% [a] (95% CI) [b]
Male	86.5% (81.2-91.9)	86.5% (81.4-91.6)	85.2% (80.6-89.9)	85.8% (80.4-91.1)	85.1% (79.6-90.6)
Female	13.5% (8.1-18.8)	13.5% (8.4-18.6)	13.2% (8.8-17.7)	12.3% (7.2-17.3)	13.2% (7.8-18.5)
Transgender [c]	0.0%	0.0%	1.5%* (0.0-3.1)	2.0%* (0.1-3.1)	1.7%* (0.2-3.2)
Sexual Orientation					
Lesbian or gay	57.3% (48.5-66.2)	57.9% (50.4-65.4)	57.4% (50.0-64.9)	59.0% (51.0-67.0)	60.0% (52.0-68.0)
Heterosexual or straight	34.4% (26.0-42.8)	23.4% (17.2-29.6)	27.1% (20.7-33.4)	29.4% (22.2-36.6)	27.4% (20.0-34.7)
Bisexual	4.3% (1.2-7.5)*	13.2% (7.9-18.5)	12.6% (7.1-18.0)	6.2%* (2.3-10.0)	7.2%* (3.9-10.5)
Other	3.9%* (0.1-7.8)	5.5%* (1.4-9.5)	2.9%* (0.8-5.1)	5.4%* (1.8-9.0)	5.4%* (0.8-10.0)
Race/Ethnicity					
American Indian/Alaska Native	0.0%	2.0% (0.0-4.5)	1.2%* (0.0-2.5)	1.0%* (0.0-2.4)	2.4%* (0.0-5.7)
Asian	0.7%* (0.0-2.1)	2.2%* (0.3-4.1)	3.8%* (0.6-7.0)	5.0%* (1.1-8.9)	1.2%* (0.0-2.5)
Black/African American	13.7% (8.0-19.4)	18.8% (12.7-24.9)	15.6% (10.4-20.9)	12.9% (7.9-18.0)	10.3% (5.6-15.0)
Latinx [d]	36.6% (27.6-45.7)	29.4% (22.6-36.3)	35.5% (28.6-42.4)	33.7% (26.0-41.5)	39.9% (32.2-47.5)
Native Hawaiian/Other Pacific Islander	0.1%* (0.0-0.3)	0.0%	0.4%* (0.0-1.1)	0.0%	0.8%* (0.0-1.9)
White	41.0% (32.2-49.8)	39.1% (32.0-46.3)	39.7% (32.1-47.3)	40.1% (31.9-48.2)	42.6% (34.5-50.7)
Multiple races	7.8% (3.3-12.3)	8.4% (3.9-13.0)	3.9%* (1.5-6.3)	7.2%* (2.3-12.2)	2.8%* (0.7-4.9)

Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Age at Time of Interview (yr)					
18–24	0.6%* (0.0-1.9)	1.6%* (0.0-3.3)	2.3%* (0.0-4.8)	3.8%* (0.0-8.3)	4.6%* (1.2-8.0)
25–29	3.1%* (0.0-7.0)	7.0% (3.3-10.8)	4.3%* (0.8-7.7)	4.3%* (0.0-9.1)	5.6%* (2.9-8.4)
30–34	7.3%* (1.9-12.6)	9.1% (4.8-13.4)	8.0% (3.9-12.0)	3.4%* (0.7-6.1)	4.9%* (2.4-7.4)
35–39	8.2% (3.4-12.9)	5.4% (2.3-8.6)	8.0% (3.9-12.0)	8.4%* (4.1-12.6)	7.6%* (2.8-12.3)
40–44	10.2%* (3.4-17.0)	14.3% (8.6-20.1)	8.5% (4.8-12.1)	10.7%* (5.1-16.3)	5.4%* (2.5-8.3)
45–49	12.1% (7.0-17.2)	13.8% (8.6-19.1)	11.1% (6.3-15.8)	10.3%* (5.9-16.3)	11.6%* (6.5-16.7)
50–54	23.6% (15.8-31.5)	18.9% (13.4-24.4)	19.2% (13.4-25.1)	19.3% (12.8-25.8)	11.2%* (7.1-15.4)
55–59	12.1% (7.0-17.2)	13.4% (8.0-18.8)	17.7% (12.1-23.3)	11.0% (6.7-15.4)	23.8% (15.9-31.6)
60–64	16.3% (10.1-22.4)	8.2% (4.5-11.9)	12.5% (6.9-18.1)	12.7% (7.9-17.6)	14.5%* (8.6-20.4)
≥65	6.5%* (2.5-10.5)	8.1% (4.1-12.2)	8.5% (4.5-12.5)	16.0%* (9.7-22.3)	10.8%* (6.6-15.0)
Education					
Less than high school	18.8% (12.0-25.6)	8.9% (4.9-12.9)	10.4% (6.3-14.4)	20.7% (13.4-28.0)	13.0% (7.8-18.2)
High school diploma or GED	19.4% (12.2-26.7)	15.4% (10.5-20.3)	26.3% (19.6-33.0)	20.3% (14.0-26.6)	19.3% (13.4-25.2)
More than high school	61.8% (53.1-70.5)	75.7% (69.7-81.7)	63.3% (56.1-70.5)	59.0% (50.8-67.3)	67.7% (60.4-74.9)
Country or Territory of Birth					
United States or U.S. territory	75.0% (67.1-83.0)	80.7% (74.8-86.7)	75.3% (69.4-81.3)	77.1% (70.5-83.6)	74.2% (67.5-81.0)
Foreign born	25.0% (17.0-32.9)	19.3% (13.3-25.2)	24.7% (18.7-30.6)	22.9% (16.4-29.5)	25.8% (19.0-32.5)

Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Time Since HIV Diagnosis					
<5 years	18.0% (10.4-25.6)	20.8% (14.8-26.9)	16.6% (10.9-22.2)	14.0%* (8.0-19.9)	12.7% (7.5-17.9)
5–9 years	22.2% (14.5-30.0)	17.8% (12.3-23.3)	21.1% (14.8-27.4)	18.3%* (11.6-24.9)	20.6% (14.3-26.8)
≥10 years	59.8% (50.7-68.9)	61.4% (54.2-68.6)	62.3% (54.9-69.7)	67.8% (59.8-75.7)	66.8% (59.3-74.1)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; GED, general educational development. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. [d] Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Homeless at Any Time[c]					
Yes	13.8% (6.6-21.0)	7.9% (4.0-11.8)	12.8% (7.1-18.4)	14.9%* (8.8-21.1)	6.7%* (3.5-9.9)
No	86.2% (79.0-93.4)	92.1% (88.2-96.0)	87.2% (81.6-92.9)	85.1% (78.9-91.2)	93.3% (90.1-96.5)
Incarcerated > 24 Hours					
Yes	5.4%* (1.1-9.7)	3.2%* (0.8-5.6)	3.5%* (0.1-6.9)	1.8%* (0.0-3.6)	2.0% (0.2-3.7)
No	94.6% (90.3-98.9)	96.8% (94.4-99.2)	96.5% (93.1-99.9)	98.2% (96.4-100.0)	98.0% (96.3-99.8)
Any Disability[d]					
Yes	35.4% (26.9-43.9)	35.9% (28.8-43.0)	43.9% (36.4-51.3)	44.0% (35.7-52.2)	39.1% (31.3-46.9)
No	64.6% (56.1-73.1)	64.1% (57.0-71.2)	56.1% (48.7-63.6)	56.0% (47.8-64.3)	60.9% (53.1-68.7)

Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Received Supplemental Security Income (SSI)					
Yes	20.5% (13.2-27.7)	14.9% (9.5-20.3)	18.2% (12.7-23.6)	18.4% (11.9-24.9)	15.6% (9.4-21.7)
No	79.5% (72.3-86.8)	85.1% (79.7-90.5)	81.8% (76.4-87.3)	81.6% (75.1-88.1)	84.4% (78.3-90.6)
Received Social Security Disability Insurance (SSDI)					
Yes	31.4% (23.3-39.5)	26.1% (19.6-32.6)	23.4% (17.1-29.6)	18.3% (12.2-24.3)	17.6% (11.2-23.9)
No	68.6% (60.5-76.7)	73.9% (67.4-80.4)	76.6% (70.4-82.9)	81.7% (75.7-87.8)	82.4% (76.1-88.8)
Went Without Food Due to Lack of Money					
Yes	22.3% (14.6-30.1)	22.7% (16.1-29.3)	20.2% (14.0-26.4)	16.7% (10.5-22.8)	17.5% (11.1-23.9)
No	77.7% (69.9-85.4)	77.3% (70.7-83.9)	79.8% (73.6-86.0)	83.3% (77.2-89.5)	82.5% (76.1-88.9)
Employment Status[e]					
Employed	44.4% (35.3-53.5)	49.2% (41.7-56.7)	45.7% (38.2-53.3)	46.9% (38.5-55.3)	51.6% (43.5-59.7)
Unemployed	40.2% (31.5-48.9)	37.6% (30.4-44.8)	40.5% (33.0-47.9)	36.7% (28.7-44.6)	34.0% (26.1-41.9)
Student	3.4%* (0.6-6.2)	1.6%* (0.0-3.2)	2.4%* (0.2-4.5)	2.0%* (0.0-4.0)	1.4%* (0.0-2.9)
Retired	12.0% (6.3-17.6)	11.6% (6.5-16.7)	11.5% (6.6-16.3)	14.4%* (8.2-20.6)	13.0%* (7.1-18.9)
Combined Yearly Household Income (U.S.$)[f]					
0–19,999	46.1% (37.1-55.1)	39.5% (32.2-46.8)	40.5% (33.0-48.0)	44.1% (35.8-52.5)	32.7% (25.0-40.4)
20,000–39,999	24.4% (16.6-32.2)	25.4% (18.2-32.5)	26.3% (19.4-33.1)	23.5% (16.6-30.4)	18.8% (12.8-24.7)
40,000–74,999	17.3% (10.7-23.9)	16.9% (11.2-22.5)	18.5% (12.1-24.8)	19.4%* (11.8-27.1)	24.4% (16.8-32.1)
≥75,000	12.2% (6.6-17.9)	18.3% (12.7-23.9)	14.8% (9.6-20.0)	12.9%* (7.0-18.9)	24.1% (16.7-31.4)

Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b
Poverty Guidelines[g]					
Above poverty threshold	66.7% (58.2-75.2)	77.6% (71.8-83.5)	72.6% (66.1-79.1)	67.0% (59.2-74.8)	74.3% (67.0-81.6)
At or below poverty threshold	33.3% (24.8-41.8)	22.4% (16.5-28.2)	27.4% (20.9-33.9)	33.0% (25.2-40.8)	25.7% (18.4-33.0)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; U.S.$, U.S. dollar. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Living on the street, in a shelter, in a single-room–occupancy hotel, or in a car. [d] Includes physical, mental, and emotional disabilities. [e] Employed includes employed for wages, self-employed, or homemaker. [f] Income from all sources, before taxes, in the last calendar year. [g] Poverty guidelines as defined by Federal Health and Human Services.

Appendix Table 3.3. Health Insurance Coverage, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b	%a (95% CI)b
Health Insurance or Coverage for Medications[c]					
Yes	98.6% (95.8-100.0)	100.0%	98.8% (96.6-100.0)	98.6% (96.5-100.0)	100.0%
No	1.4%* (0.0-4.2)	0.0%	1.2%* (0.0-3.4)	1.4%* (0.0-3.5)	0.0%
Type of Health Insurance or Coverage for Medications:					
Ryan White or ADAP					
Yes	52.8% (43.7-61.8)	47.5% (40.1-55.0)	46.2% (38.6-53.7)	46.1% (37.7-54.5)	45.7% (37.5-53.8)
No	47.2% (38.2-56.3)	52.5% (45.0-59.9)	53.8% (46.3-61.4)	53.9% (45.5-62.3)	54.3% (46.2-62.5)
Medicaid					
Yes	51.5% (42.4-60.6)	57.7% (50.3-65.1)	51.3% (43.7-58.9)	58.5% (50.3-66.8)	45.9% (37.8-54.1)
No	48.5% (39.4-57.6)	42.3% (34.9-49.7)	48.7% (41.1-56.3)	41.5% (33.2-49.7)	54.1% (45.9-62.2)

Appendix Table 3.3. Health Insurance Coverage, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Private Health Insurance					
Yes	32.4% (24.1-40.7)	38.4% (31.2-45.5)	40.2% (32.7-47.7)	33.6% (25.3-41.8)	39.5% (31.6-47.4)
No	67.6% (59.3-75.9)	61.6% (54.5-68.8)	59.8% (52.3-67.3)	66.4% (58.2-74.7)	60.5% (52.6-68.4)
Medicare					
Yes	27.6% (20.2-35.0)	34.7% (27.4-41.9)	33.6% (26.3-41.0)	32.4% (24.8-40.0)	27.0% (19.5-34.5)
No	72.4% (65.0-79.8)	65.3% (58.1-72.6)	66.4% (59.0-73.7)	67.6% (60.0-75.2)	73.0% (65.5-80.5)
Other Public Insurance					
Yes	12.5% (5.6-19.3)	10.7% (6.3-15.2)	10.6% (5.4-15.8)	11.4%* (6.3-16.5)	5.2%* (2.4-8.0)
No	87.5% (80.7-94.4)	89.3% (84.8-93.7)	89.4% (84.2-94.6)	88.6% (83.5-93.7)	94.8% (92.0-97.6)
Tricare/CHAMPUS or Veterans Administration					
Yes	4.2%* (1.1-7.2)	5.7%* (1.3-10.1)	7.2%* (1.9-12.4)	7.1%* (1.8-12.3)	9.5%* (3.3-15.6)
No	95.8% (92.8-98.9)	94.3% (89.9-98.7)	92.8% (87.6-98.1)	92.9% (87.7-98.2)	90.5% (84.4-96.7)
Insurance Type Unknown[d]					
Yes	1.2%* (0.0-2.8)	0.0%	0.4%* (0.0-1.1)	0.0%	0.5%* (0.0-1.4)
No	98.8% (97.2-100.0)	100.0%	99.6% (98.9-100.0)	100.0%	99.5% (98.6-100.0)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; CHAMPUS, Civilian Health and Medical Program of the Uniformed Services; ADAP, AIDS Drug Assistance Program. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] People could select more than 1 response for health insurance or coverage for medications (including antiretroviral medications). [d] Unknown insurance type means that the person had insurance or coverage for medications (including antiretroviral medications), but the type of insurance or coverage could not be determined.

Appendix Table 4.1. HIV Disease Stage, CD4+ Lymphocyte Counts, and Viral Suppression, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
HIV Infection Stage 3 (AIDS)[c]					
Yes	57.4% (48.6-66.2)	59.1% (51.7-66.5)	55.1% (47.5-62.7)	57.8% (49.4-66.1)	58.1% (50.1-66.1)
No	42.6% (33.8-51.4)	40.9% (33.5-48.3)	44.9% (37.3-52.5)	42.2% (33.9-50.6)	41.9% (33.9-49.9)
Geometric Mean CD4 Count (cells/μL)					
0–199	11.0% (4.9-17.1)	8.3% (4.2-12.3)	3.7%* (0.9-6.5)	4.6%* (0.6-8.5)	4.7%* (1.5-7.8)
200–349	6.7% (3.0-10.4)	9.7% (4.7-14.7)	12.9% (7.7-18.1)	8.0%* (2.5-13.5)	10.9%* (6.1-15.6)
350–499	18.6% (11.6-25.6)	21.6% (14.6-28.6)	18.6% (12.3-24.9)	19.4%* (11.4-27.4)	21.4% (13.3-29.5)
≥500	63.8% (54.8-72.7)	60.4% (52.4-68.5)	64.8% (57.2-72.5)	68.1% (58.5-77.6)	63.1% (54.5-71.6)
Lowest CD4 Count (cells/μL), Past 12 Months					
0–49	2.4%* (0.0-5.1)	2.7%* (0.3-5.0)	3.8%* (0.5-7.2)	0.0%	1.1%* (0.0-2.7)
50–199	10.1% (4.3-15.9)	9.2% (4.3-14.0)	6.4%* (2.6-10.2)	6.0%* (1.2-10.9)	6.2% (2.6-9.7)
200–349	9.3% (4.7-13.9)	12.3% (7.5-17.1)	12.5% (7.4-17.5)	10.7%* (4.7-16.7)	17.4%* (10.6-24.3)
350–499	19.4% (12.4-26.4)	21.8% (14.8-28.7)	17.7% (11.5-23.8)	22.1%* (13.6-30.6	23.1% (14.9-31.4)
≥500	58.8% (49.6-67.9)	54.1% (46.0-62.2)	59.7% (51.8-67.5)	61.2% (51.1-71.3)	52.1% (43.4-60.9)
Viral Suppression					
Most recent viral load documented undetectable or <200 copies/mL	75.1% (67.4-82.9)	70.9% (63.7-78.1)	68.3% (61.0-75.6)	49.2% (40.9-57.4)	66.9% (59.0-74.8)
Most recent viral load documented detectable, ≥200 copies/mL, or missing/unknown	24.9% (17.1-32.6)	29.1% (21.9-36.3)	31.7% (24.4-39.0)	50.8% (42.6-59.1)	33.1% (25.2-41.0)

Appendix Table 4.1. HIV Disease Stage, CD4+ Lymphocyte Counts, and Viral Suppression, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Sustained Viral Suppression					
All viral load measurements documented undetectable or <200 copies/mL	68.7% (60.2-77.2)	64.5% (57.2-71.9)	64.3% (56.8-71.8)	46.8% (38.6-55.0)	62.6% (54.7-70.6)
Any viral load ≥200 copies/mL or missing/unknown	31.3% (22.8-39.8)	35.5% (28.1-42.8)	35.7% (28.2-43.2)	53.2% (45.0-61.4)	37.4% (29.4-45.3)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CD4, CD4 T-lymphocyte count (cells/μL); CI, confidence interval. Source of disease stage information: CDC. Revised surveillance case definition for HIV infection–United States, 2014. MMWR 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/indrr-2014.html. Accessed August 21, 2019. Note: CD4 counts and viral load measurements are from medical record abstraction. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] HIV infection, stage 3 (AIDS): documentation of an AIDS-defining condition or either a CD4 count of <200 cells/μL or a CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.

Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Ever Received Outpatient HIV Care[c]					
Yes	100.0%	100.0%	100.0%	100.0%	100.0%
No	0.0%	0.0%	0.0%	0.0%	0.0%
Received Outpatient HIV Care, Past 12 Months[c]					
Yes	98.3% (95.4-100.0)	100.0%	98.9% (96.6-100.0)	88.1% (80.5-95.6)	97.7% (93.9-100.0)
No	1.7%* (0.0-4.6)	0.0%	1.1%* (0.0-3.4)	11.9%* (4.4-19.5)	2.3%* (0.0-6.1)
Received Outpatient HIV Care, Past 24 Months[c]					
Yes	98.3% (95.4-100.0)	100.0%	98.9% (96.6-100.0)	97.2% (92.9-100.0)	100.0%
No	1.7%* (0.0-4.6)	0.0%	1.1%* (0.0-3.4)	2.8%* (0.0-7.1)	0.0%

Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Retained in Care, Past 12 Months[d]					
Yes	86.8% (79.9-93.7)	80.8% (74.2-87.4)	84.3% (78.5-90.2)	68.4% (58.5-78.2)	74.9% (66.7-83.2)
No	13.2% (6.3-20.1)	19.2% (12.6-25.8)	15.7% (9.8-21.5)	31.6% (21.8-41.5)	25.1% (16.8-33.3)
Retained in Care, Past 24 Months[d]					
Yes	65.8% (57.0-74.7)	59.0% (51.4-66.6)	63.0% (55.4-70.5)	50.3% (40.8-59.8)	52.8% (44.4-61.1)
No	34.2% (25.3-43.0)	41.0% (33.4-48.6)	37.0% (29.5-44.6)	49.7% 40.2-59.2)	47.2% (38.9-55.6)
Prescribed ART, Past 12 Months[e]					
Yes	89.1% (83.5-94.6)	82.7% (76.4-89.0)	82.6% (76.2-89.1)	56.8% (48.4-65.2)	81.2% (74.0-88.4)
No	10.9% (5.4-16.5)	17.3% (11.0-23.6)	17.4% (10.9-23.8)	43.2% (34.8-51.6)	18.8% (11.6-26.0)
Prescribed PCP Prophylaxis, Past 12 Months[f]					
Yes	25.0%* (2.7-47.4)	50.3%* (25.3-75.4)	18.3%* (0.0-38.1)	37.9%* (0.0-79.1)	41.0%* (14.4-67.5)
No	75.0%* (52.6-97.3)	49.7%* (24.6-74.7)	81.7%* (61.9-100.0)	62.1%* (20.9-100.0)	59.0%* (32.5-85.6)
Prescribed MAC Prophylaxis, Past 12 Months[g]					
Yes	34.4%* (0.0-89.3)	0.0%	0.0%	0.0%	0.0%
No	65.6%* (10.7-100.0)	100.0%	100.0%	0.0%	0.0%
Received Influenza Vaccination, Past 12 Months					
Yes	80.8% (73.5-88.1)	72.5% (65.4-79.5)	81.9% (76.1-87.7)	73.6% (65.7-81.5)	80.9% (75.2-86.6)
No	19.2% (11.9-26.5)	27.5% (20.5-34.6)	18.1% (12.3-23.9)	26.4% (18.5-34.3)	19.1% (13.4-24.8)

Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ
TOTAL	176	221	229	192	218

Abbreviations: CI, confidence interval; ART, antiretroviral therapy; PCP, Pneumocystis pneumonia; MAC, Mycobacterium avium complex; CD4, CD4 T-lymphocyte count (cells/µL). Note: CD4 counts, viral load measurements, prophylaxes, and vaccinations are from medical record abstraction. Measurement period is the 12 months before the interview unless otherwise noted. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. ª Percentages are weighted percentages. ᵇ CIs incorporate weighted percentages. ᶜ Outpatient HIV care was defined as any documentation of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis. ᵈ Two elements of outpatient HIV care at least 90 days apart in each 12-month period. ᵉ ART prescription documented in medical record; persons with no medical record abstraction were considered to have no documentation of ART prescription. ᶠ Among persons with CD4 cell count <200 cells/µL. ᵍ Among persons with CD4 cell count <50 cells/µL.

Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ	%ª (95% CI)ᵇ
Ever Taken ART					
Yes	98.3% (96.4-100.0)	97.1% (93.8-100.0)	99.3% (98.0-100.0)	99.2% (98.1-100.0)	99.7% (99.1-100.0)
No	1.7%* (0.0-3.6)	2.9%* (0.0-6.2)	0.7%* (0.0-2.0)	0.8%* (0.0-1.9)	0.3%* (0.0-0.9)
Currently Taking ART					
Yes	92.2% (87.3-97.2)	94.4% (90.1-98.7)	93.9% (89.4-98.3)	93.5% (88.3-98.8)	99.7% (99.1-100.0)
No	7.8%* (2.8-12.7)	5.6%* (1.3-9.9)	6.1%* (1.7-10.6)	6.5%* (1.2-11.7)	0.3%* (0.0-0.9)
Reasons for Never Taking ARTᶜ:					
Health care provider never discussed taking ART with person					
Yes	0.0%*	0.0%*	0.0%*	0.0%*	0.0%*
No	100.0%*	100.0%*	100.0%*	100.0%*	100.0%*

Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Health care provider said person should not start taking ART					
Yes	100.0%*	41.4%* (0.0-100.0)	100.0%*	25.8%* (0.0-79.1)	0.0%*
No	0.0%*	58.6%* (0.0-100.0)	0.0%*	74.2%* (20.9-100.0)	100.0%*
Money or insurance problems					
Yes	33.8%* (0.0-87.7)	0.0%*	0.0%*	0.0%*	0.0%*
No	66.2%* (12.3-100.0)	100.0%*	100.0%*	100.0%*	100.0%*
Person doesn't believe he/she needs ART					
Yes	7.5%* (0.0-24.2)	17.3%* (0.0-51.9)	100.0%*	74.2%* (20.9-100.0)	100.0%*
No	92.5% (75.8-100.0)	82.7%* (48.1-100.0)	0.0%*	25.8%* (0.0-79.1)	0.0%*
Person thinks ART would make him/her feel sick or harm him/her					
Yes	41.8%* (0.0-100.0)	0.0%*	100.0%*	74.2%* (20.9-100.0)	100.0%*
No	58.2%* (0.0-100.0)	100.0%*	0.0%*	25.8%* (0.0-79.1)	0.0%*
Person decided not to take ART for some other reason					
Yes	6.0%* (0.0-19.1)	58.6%* (0.0-100.0)	0.0%*	0.0%*	100.0%*
No	94.0%* (80.9-100.0)	41.4%* (0.0-100.0)	100.0%*	100.0%*	0.0%*
Reasons for Not Currently Taking ART, Among Those Persons With a History of ART Use[c]:					
Health care provider never discussed restarting ART with person					
Yes	23.3%* (0.0-61.8)	44.7%* (0.0-99.8)	42.2%* (0.8-83.7)	46.8%* (0.0-95.3)	0.0%*
No	76.7%* (38.2-100.0)	55.3%* (0.2-100.0)	57.8%* (16.3-99.2)	53.2%* (4.7-100.0)	0.0%*

Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Health care provider said person should not take ART					
Yes	9.5%* (0.0-28.0)	6.1%* (0.0-19.2)	0.0%	0.0%	0.0%
No	90.5%* (72.0-100.0)	93.9%* (80.8-100.0)	100.0%*	100.0%*	0.0%
Money or insurance problems					
Yes	30.9%* (0.0-69.5)	93.9%* (80.8-100.0)	43.5%* (3.5-83.5)	0.0%	0.0%
No	69.1%* (30.5-100.0)	6.1%* (0.0-19.2)	56.5%* (16.5-96.5)	100.0%*	0.0%
Person doesn't believe he/she needs ART					
Yes	39.0%* (0.0-78.0)	6.1%* (0.0-19.2)	77.6%* (48.4-100.0)	34.2%* (0.0-73.6)	0.0%
No	61.0%* (22.0-100.0)	93.9%* (80.8-100.0)	22.4%* (0.0-51.6)	65.7%* (26.4-100.0)	0.0%
Person thinks ART would make him/her feel sick or harm him/ her					
Yes	15.6%* (0.0-37.6)	0.0%*	50.1%* (9.5-90.7)	71.2%* (30.0-100.0)	0.0%
No	84.4%* (62.4-100.0)	100.0%*	49.9%* (9.3-90.5)	28.8%* (0.0-70.0)	0.0%
Person decided not to take ART for some other reason					
Yes	38.3%* (2.8-73.7)	61.8%* (15.6-100.0)	42.5%* (1.0-83.9)	86.8%* (61.2-100.0)	0.0%
No	61.7%* (26.3-97.2)	38.2%* (0.0-84.4)	57.5%* (16.1-99.0)	13.2%* (10.0-38.8)	0.0%
TOTAL	176	221	229	192	218

Abbreviation: CI, confidence interval. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] People could select more than one response for reasons not taking ART.

Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
ART Adherence in the Past 30 Days:					
How many days did you miss at least 1 dose of any of your HIV medicines?					
0	60.3% (51.2-69.4)	56.9% (49.3-64.5)	63.4% (56.0-70.7)	57.4% (49.1-65.7)	59.2% (51.5-67.0)
1–2	21.8% (14.2-29.5)	29.6% (22.6-36.7)	26.9% (20.3-33.6)	22.3% (15.9-28.9)	28.4% (21.7-35.2)
3–5	12.9% (7.0-18.8)	10.6% (5.4-15.9)	5.4% (2.5-8.3)	13.3%* (6.8-19.8)	8.4%* (3.5-13.3)
6–10	2.5%* (0.0-6.5)	2.7%* (0.7-4.8)	3.8%* (0.2-7.4)	3.1%* (0.0-6.4)	2.3%* (0.4-4.2)
11+	2.5%* (0.0-4.9)	0.1%* (0.0-0.4)	0.5%* (0.0-1.4)	3.8%* (1.1-6.5)	1.6%* (0.0-3.2)
How well did you do at taking your HIV medicines in the way you were supposed to?					
Very poor	0.5%* (0.0-1.5)	0.4%* (0.0-1.3)	1.3%* (0.0-2.7)	1.7%* (0.0-3.5)	0.0%
Poor	3.1%* (0.0-6.7)	2.2%* (0.0-4.9)	0.8%* (0.0-1.9)	1.5%* (0.0-3.1)	1.5%* (0.0-3.1)
Fair	9.3%* (2.8-15.9)	6.5%* (2.6-10.4)	5.6%* (1.6-9.6)	7.1%* (2.5-11.6)	3.1%* (0.9-5.4)
Good	4.7%* (1.6-7.7)	17.7% (11.8-23.6)	14.1% (9.0-19.2)	13.3%* (7.6-19.1)	9.8%* (4.0-15.7)
Very good	27.6% (19.6-35.7)	23.9% (17.4-30.5)	22.6% (16.9-28.4)	27.5% (20.0-35.0	32.1% (24.7-39.4)
Excellent	54.8% (45.4-64.1)	49.3% (41.7-56.8)	55.6% (48.1-63.1)	48.9% (40.5-57.3)	53.4% (45.3-61.5)
How often did you take your HIV medicines in the way you were supposed to?					
Never	0.5%* (0.0-1.5)	1.8%* (0.0-4.6)	0.0%	1.8%* (0.0-3.6)	0.0%
Rarely	0.7%* (0.0-1.9)	0.4%* (0.0-1.3)	0.9%* (0.0-2.1)	0.6%* (0.0-1.6)	0.7%* (0.0-1.7)
Sometimes	1.3%* (0.0-2.9)	1.2%* (0.0-2.5)	3.7%* (0.2-7.3)	4.4%* (0.2-8.6)	2.1%* (0.3-3.9)
Usually	4.0%* (0.9-7.2)	5.6%* (2.0-9.2)	3.7%* (1.2-6.1)	3.0%* (0.7-5.2)	1.3%* (0.0-2.6)

Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
How often did you take your HIV medicines in the way you were supposed to? (cont.)					
Almost always	26.4% (17.9-34.8)	30.0% (22.9-37.1)	26.0% (19.7-32.4)	18.4% (12.2-24.7)	30.1% (22.5-37.7)
Always	67.2% (58.4-76.0)	61.0% (53.5-68.5)	65.7% (58.6-72.7)	71.7% (64.3-79.2)	65.8% (58.1-73.6)
How often were you troubled by ART side effects?					
Never	64.7% (55.9-73.4)	60.0% (52.6-67.5)	68.1% (61.0-75.3)	72.3% (65.1-79.5)	75.7% (69.4-82.0)
Rarely	16.9% (10.5-23.4)	22.6% (16.2-29.1)	17.7% (12.0-23.4)	15.1% (9.6-20.6)	13.7% (9.1-18.3)
About half the time	10.0% (4.3-15.6)	5.7%* (2.1-9.3)	5.5% (2.4-8.6)	5.4%* (1.2-9.7)	3.7%* (0.4-7.1)
Most of the time	3.1%* (0.3-5.9)	6.8% (2.8-10.7)	6.0%* (1.7-10.3)	4.6%* (1.5-7.7)	4.9%* (2.1-7.7)
Always	5.3%* (0.9-9.8)	4.8%* (1.8-7.9)	2.7%* (0.7-4.7)	2.6%* (0.5-4.7)	2.0%* (0.2-3.8)
Reasons for Last Missed ART Dose[c]:					
Had a problem getting a prescription, a refill, insurance coverage, or paying for HIV medicines					
Yes	17.3% (10.4-24.2)	21.1% (14.9-27.4)	23.0% (16.1-29.9)	28.2% (18.9-37.6)	17.8%* (10.0-25.6)
No	82.7% (75.8-89.6)	78.9% (72.6-85.1)	77.0% (70.1-83.9)	71.8% (62.4-81.1)	82.2% (74.4-90.0)
In the hospital or too sick to take HIV medicines					
Yes	9.8%* (3.5-16.2)	6.8% (3.3-10.2)	7.3% (4.0-10.5)	5.2%* (1.8-8.6)	8.0%* (2.7-13.2)
No	90.2% (83.8-96.5)	93.2% (89.8-96.7)	92.7% (89.5-96.0)	94.8% (91.4-98.2)	92.0% (86.8-97.3)
Fell asleep early or overslept					
Yes	35.0% (25.8-44.2)	32.3% (25.1-39.6)	35.8% (28.6-43.0)	41.8% (32.7-50.9)	35.7% (27.3-44.2)
No	65.0% (55.8-74.2)	67.7% (60.4-74.9)	64.2% (57.0-71.4)	58.2% (49.1-67.3)	64.3% (55.8-72.7)

Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015 %[a] (95% CI)[b]	2016 %[a] (95% CI)[b]	2017 %[a] (95% CI)[b]	2018 %[a] (95% CI)[b]	2019 %[a] (95% CI)[b]
Change in your daily routine or were out of town					
Yes	34.4% (25.9-43.0)	31.6% (24.7-38.4)	37.9% (30.5-45.3)	45.3% (35.9-54.6)	40.2% (31.6-48.8)
No	65.6% (57.0-74.1)	68.4% (61.6-75.3)	62.1% (54.7-69.5)	54.7% (45.4-64.1)	59.8% (51.2-68.4)
Had side effects from your HIV medicines					
Yes	5.3%* (1.7-8.9)	11.0% (5.7-16.2)	9.2% (5.5-12.9)	12.3%* (6.1-18.4)	9.0%* (4.8-13.1)
No	94.7% (91.1-98.3)	89.0% (83.8-94.3)	90.8% (87.1-94.5)	87.7% (81.6-93.9)	91.0% (86.9-95.2)
Felt depressed or overwhelmed					
Yes	18.1% (10.8-25.5)	14.7% (9.5-20.0)	13.7% (9.0-18.4)	18.5%* (11.2-25.7)	17.5% (11.0-24.0)
No	81.9% (74.5-89.2)	85.3% (80.0-90.5)	86.3% (81.6-91.0)	81.5% (74.3-88.8)	82.5% (76.0-89.0)
Was drinking or using drugs					
Yes	5.3%* (0.7-9.9)	9.7% (5.6-13.9)	7.2% (3.0-11.4)	8.8%* (4.2-13.5)	11.3%* (6.7-15.9)
No	94.7% (90.1-99.3)	90.3% (86.1-94.4)	92.8% (88.6-97.0)	91.2% (86.5-95.8)	88.7% (84.1-93.3)
Forgot to take HIV medicines					
Yes	55.7% (46.3-65.1)	63.1% (56.0-70.3)	50.3% (42.6-58.0)	64.7% (55.6-73.9)	69.3% (60.8-77.8)
No	44.3% (34.9-53.7)	36.9% (29.7-44.0)	49.7% (42.0-57.4)	35.3% (26.1-44.4)	30.7% (22.2-39.2)
Did not feel like taking HIV medicines					
Yes	9.8% (4.5-15.0)	16.7% (10.5-22.9)	13.4% (8.1-18.6)	11.6%* (6.3-17.0)	11.3%* (5.6-17.0)
No	90.2% (85.0-95.5)	83.3% (77.1-89.5)	86.6% (81.4-91.9)	88.4% (83.0-93.7)	88.7% (83.0-94.4)
TOTAL	176	221	229	192	218

Abbreviation: CI, confidence interval. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] People could report more than one reason for last missed ART dose.

Appendix Table 4.5a. Antiretroviral Therapy (ART) Prescription by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Gender					
Male	89.0% (83.0-95.0)	82.0% (75.0-89.0)	82.4% (75.2-89.5)	58.5% (49.2-67.7)	79.8% (71.6-88.0)
Female	89.7% (74.4-100.0)	87.0% (74.7-99.2)	82.5%* (65.8-99.2)	47.6% (26.2-69.0)	90.7%* (80.3-100.0)
Transgender[c]	---	---	100.0%*	42.5%* (0.0-90.8)	79.2%* (43.1-100.0)
Sexual Orientation					
Lesbian or gay	89.3% (82.4-96.2)	82.7% (74.2-91.2)	84.3% (75.7-93.0)	58.5% (46.8-70.3)	79.8% (69.7-90.0)
Heterosexual or straight	89.4% (78.8-99.9)	81.5% (68.9-94.0)	79.5% (66.9-92.0)	62.9% (49.0-76.8)	85.8% (76.4-95.1)
Bisexual	71.8% (37.7-100.0)	78.0%* (59.0-97.0)	81.9%* (62.2-100.0)	32.0%* (4.1-60.0)	78.7%* (60.0-97.5)
Other	100%*	97.7%* (92.9-100.0)	69.7%* (35.1-100.0)	33.7%* (4.0-63.3)	70.8%* (25.7-100.0)
Race/Ethnicity					
American Indian/Alaska Native	---	33.5%* (0.0-94.2)	68.4%* (16.2-100.0)	100.0%*	100.0%*
Asian	100.0%	80.1%* (44.9-100.0)	47.5%* (4.6-90.4)	29.4%* (0.0-64.8)	65.5%* (11.0-100.0)
Black/African American	94.5% (83.9-100.0)	73.9%* (55.6-92.3)	82.9%* (64.2-100.0)	58.9%* (38.4-79.3)	66.0%* (40.3-91.7)
Latinx[d]	88.4% (79.1-97.7)	80.9% (68.9-93.0)	80.2% (69.6-90.8)	53.6% (39.5-67.8)	82.9% (73.2-92.6)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	0.0%	50.0%* (0.0-100.0)
White	85.6% (75.6-95.6)	90.2% (83.6-96.8)	87.0% (69.6-90.8)	59.9% (46.5-73.2)	83.1% (71.1-95.1)
Multiple races	100.0%*	84.6%* (67.6-100.0)	100.0%*	63.8%* (23.7-100.0)	84.2%* (56.0-100.0)

Appendix Table 4.5a. Antiretroviral Therapy (ART) Prescription by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Age at Time of Interview (yr)					
18–29	84.6% (54.1-100.0)	75.8%* (50.8-100.0)	94.1% (82.4-100.0)	22.2%* (0.0-47.2)	79.5%* (64.0-95.0)
30–39	91.1% (80.3-100.0)	70.3%* (50.2-90.4)	77.5%* (58.3-96.6)	73.3%* (53.3-93.4)	79.3%* (57.2-100.0)
40–49	91.0% (81.1-100.0)	79.4% (65.5-93.3)	81.1% (66.3-95.9)	60.8%* (43.6-78.1)	88.2% (78.1-98.2)
≥50	88.1% (80.1-96.1)	89.5% (83.8-95.2)	83.3% (75.0-91.5)	43.1% (32.7-53.5)	79.9% (69.7-90.1)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. [d] Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 4.5b. Antiretroviral Therapy (ART) Dose Adherence[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Gender					
Male	60.3% (50.2-70.3)	55.7% (47.5-63.9)	63.7% (55.6-71.8)	57.5% (48.4-66.7)	59.9% (51.4-68.4)
Female	60.4% (39.7-81.2)	64.0%* (45.4-82.5)	63.4%* (47.4-79.5)	52.8%* (30.5-75.1)	60.4%* (39.6-81.3)
Transgender[d]	---	---	45.3%* (0.0-94.8)	21.2%* (0.0-59.4)	16.9%* (0.0-51.7
Sexual Orientation					
Lesbian or gay	60.1% (47.3-72.6)	56.0% (46.1-65.9)	65.9% (56.3-75.5)	62.3% (51.0-73.6)	56.4% (46.4-66.5)
Heterosexual or straight	66.0% (52.2-79.8)	62.1% (47.9-76.4)	65.6% (53.6-77.5)	54.4% (40.5-68.4)	71.1% (58.1-84.0)
Bisexual	36.5%* (0.0-77.4)	52.6%* (30.3-74.9)	48.3%* (23.2-73.4)	26.5%* (0.0-58.3)	47.7%* (23.8-71.7)
Other	29.7%* (0.0-69.9)	57.5%* (19.3-95.6)	39.4%* (3.8-75.0)	42.8%* (7.2-78.3)	43.4%* (0.0-87.5)

Appendix Table 4.5b. Antiretroviral Therapy (ART) Dose Adherence[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Race/Ethnicity					
American Indian/Alaska Native	---	59.8%* (0.0-100.0)	36.9%* (0.0-93.2)	100.0%*	18.3%* (0.0-56.2)
Asian	100.0%	59.7%* (16.3-100.0)	100.0%*	75.3%* (42.9-100.0)	65.5%* (11.0-100.0)
Black/African American	60.7%* (38.3-83.1)	49.8%* (31.4-68.2)	58.5%* (40.9-76.0)	39.8%* (20.0-59.6)	55.8%* (32.5-79.1)
Latinx[e]	53.9%* (37.2-70.5)	57.1% (43.4-70.8)	63.6% (52.8-74.3)	54.8% (40.9-68.8)	51.7% (39.8-63.7)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	0.0%	50.0%* (0.0-100.0)
White	63.3% (49.4-77.1)	58.3% (46.8-69.8)	65.0% (52.1-77.8)	64.3% (52.0-76.5)	70.3% (59.2-81.5)
Multiple races	70.5%* (45.2-95.9)	64.4%* (34.7-94.1)	40.0%* (10.0-70.0)	44.8%* (10.7-78.9)	45.7%* (8.3-83.2)
Age at Time of Interview (yr)					
18–29	76.2%* (34.8-100.0)	65.2%* (40.6-89.9)	72.3%* (47.5-97.0)	36.9%* (0.5-73.2)	30.1%* (12.1-48.2)
30–39	54.4%* (29.8-78.9)	54.3%* (35.1-73.4)	56.4%* (37.9-74.8)	46.1%* (23.6-68.7)	35.7%* (12.4-58.9)
40–49	57.3%* (36.2-78.4)	57.8%* (42.2-73.5)	66.0% (51.5-80.5)	72.4%* (57.8-87.0)	58.5%* (41.2-75.9)
≥50	62.2% (51.1-73.3)	55.9% (45.5-66.2)	63.1% (53.2-73.0)	56.9% (46.5-67.2)	69.3% (59.9-78.8)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval. [a] In past 30 days, 100% adherence to ART doses. [b] Percentages are weighted percentages. [c] CIs incorporate weighted percentages. [d] People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender.

[e] Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 4.5c. Sustained Viral Suppression[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Gender					
Male	68.2% (58.9-77.5)	62.4% (54.3-70.4)	64.2% (55.9-72.4)	52.8% (43.8-61.8)	39.3% (30.5-48.1)
Female	71.7%* (51.4-91.9)	78.3%* (62.3-94.2)	65.2%* (46.9-83.4)	55.1%* (33.9-76.1)	19.0%* (4.4-33.5)
Transgender[d]	---	---	67.0%* (16.5-100.0)	57.5%* (9.2-100.0)	81.5%* (48.3-100.0)
Sexual Orientation					
Lesbian or gay	73.5% (62.7-84.2)	63.7% (54.1-73.4)	69.0% (59.2-78.9)	54.5% (43.2-65.9)	34.8% (24.4-45.3)
Heterosexual or straight	62.4% (47.6-77.1)	71.6% (58.2-85.0)	57.6% (44.2-71.0)	44.8%* (30.8-58.7)	38.9%* (23.5-54.2)
Bisexual	71.8%* (37.7-100.0)	54.3%* (32.3-76.2)	60.7%* (36.3-85.0)	48.0%* (16.2-79.9)	47.6%* (24.5-70.8)
Other	47.6%* (0.0-96.9)	65.2%* (30.4-100.0)	67.2%* (31.0-100.0)	76.2%* (50.8-100.0)	56.6%* (12.5-100.0)
Race/Ethnicity					
American Indian/Alaska Native	---	38.5%* (0.0-94.2)	31.6%* (0.0-83.8)	41.9%* (0.0-100.0)	17.6%* (0.0-54.2)
Asian	100.0%*	59.7%* (16.3-100.0)	27.7%* (0.0-59.8)	70.6%* (35.2-100.0)	34.5%* (0.0-89.0)
Black/African American	64.9%* (43.0-86.8)	54.9%* (36.8-72.9)	71.4%* (54.3-88.5)	35.9%* (16.4-55.4)	60.4%* (38.5-82.3)
Latinx[e]	68.5% (54.2-82.8)	65.5% (52.2-78.7)	61.9% (50.2-73.6)	57.9% (44.5-71.3)	42.9% (31.1-54.7)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	0.0%	50.0%* (0.0-100.0)
White	65.6% (51.8-79.4)	74.3% (64.0-84.6)	65.3% (52.5-78.1)	51.6% (38.4-64.8)	29.1%* (16.3-41.9)
Multiple races	89.2% (74.2-100.0)	44.7%* (16.9-72.5)	90.8% (77.7-100.0)	60.5%* (28.2-92.8)	15.8%* (0.0-44.0)

Appendix Table 4.5c. Sustained Viral Suppression[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Age at Time of Interview (yr)					
18–29	81.1%* (48.9-100.0)	43.1%* (19.4-66.7)	58.0%* (25.7-90.2)	14.5%* (0.0-35.2)	52.1%* (30.2-74.0)
30–39	55.0%* (30.6-79.4)	61.3%* (42.6-79.9)	64.7%* (45.6-83.8)	64.2%* (42.7-85.6)	61.0%* (38.7-83.4)
40–49	63.9%* (44.8-83.1)	69.8%* (54.7-84.9)	66.8% (50.8-82.8)	42.5%* (24.3-60.7)	58.8%* (41.8-75.8)
≥50	73.3% (63.1-83.5)	66.2% (56.3-76.2)	64.1% (54.3-74.0)	49.4% (39.2-59.6)	65.8% (55.0-76.6)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval. [a] In past 30 days, 100% adherence to ART doses. [b] Percentages are weighted percentages. [c] CIs incorporate weighted percentages. [d] People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. [e] Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 4.6a. Sexually Transmitted Infections Testing by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Gonorrhea[c]					
Yes, received test	41.5% (32.4-50.6)	34.3% (27.3-41.4)	37.0% (29.5-44.4)	43.8% (34.3-53.3)	41.3% (33.5-49.2)
No test documented	58.5% (49.4-67.6)	65.7% (58.6-72.7)	63.0% (55.6-70.5)	56.2% (46.7-65.7)	58.7% (50.8-66.5)
Chlamydia[d]					
Yes, received test	42.4% (33.4-51.5)	36.5% (29.2-43.7)	36.9% (29.4-44.3)	44.4% (34.9-53.9)	40.8% (33.0-48.6)
No test documented	57.6% (48.5-66.6)	63.5% (56.3-70.8)	63.1% (55.7-70.6)	55.6% (46.1-65.1)	59.2% (51.4-67.0)
Syphilis[e]					
Yes, received test	59.2% (50.0-68.3)	51.6% (43.9-59.4)	57.0% (49.3-64.7)	57.2% (47.8-66.7)	54.6% (46.0-63.1)
No test documented	40.8% (31.7-50.0)	48.4% (40.6-56.1)	43.0% (35.3-50.7)	42.8% (33.3-52.2)	45.4% (36.9-54.0)

Appendix Table 4.6a. Sexually Transmitted Infections Testing by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Gonorrhea, Chlamydia, and Syphilis					
Yes, received all 3 tests	38.0% (29.0-46.9)	31.0% (24.2-37.7)	32.7% (25.6-39.8)	41.5% (32.0-50.9)	36.7% (29.2-44.2)
Fewer than 3 tests documented	62.0% (53.1-71.0)	69.0% (62.3-75.8)	67.3% (60.2-74.4)	58.5% (49.1-68.0)	63.3% (55.8-70.8)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody; EIA, enzyme immunoassay; ELISA, enzyme-linked immunoassay; FTA-ABS, fluorescent treponemal antibody absorbed; MHA-TP, microhemagglutination assay for antibody to Treponema pallidum; NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; TP-PA, T. pallidum particle agglutination; TPHA, T. pallidum hemagglutination assay; VDRL, Venereal Disease Research Laboratory. Note: Information on laboratory testing for sexually transmitted diseases was based on medical record abstraction. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Testing for Neisseria gonorrhoeae was defined as documentation of a result from culture, gram stain, EIA, NAAT, or nucleic acid probe. [d] Chlamydia trachomatis testing was defined as a result from culture, DFA, EIA or ELISA, NAAT, or nucleic acid probe. [e] Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy.

Appendix Table 4.6b. Sexually Transmitted Infections Testing Among Sexually Active[a] People Living With Diagnosed HIV, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Gonorrhea[d]					
Yes, received test	46.2% (34.1-58.3)	35.9% (26.5-45.3)	43.8% (33.6-54.0)	55.6% (43.2-68.0)	45.2% (34.3-56.0)
No test documented	53.8% (41.7-65.9)	64.1% (54.7-73.5)	56.2% (46.0-66.4)	44.4% (32.0-56.8)	54.8% (44.0-65.7)
Chlamydia[e]					
Yes, received test	47.7% (35.6-59.8)	39.6% (29.7-49.4)	43.7% (33.5-53.8)	55.6% (43.2-68.0)	45.2% (34.3-56.0)
No test documented	52.3% (40.2-64.4)	60.4% (50.6-70.3)	56.3% (46.2-66.5)	44.4% (32.0-56.8)	54.8% (44.0-65.7)
Syphilis[f]					
Yes, received test	62.9% (50.8-75.1)	49.2% (38.9-59.5)	64.2% (54.2-74.1)	67.2% (55.6-78.8)	56.0% (44.4-67.7)
No test documented	37.1% (24.9-49.2)	50.8% (40.5-61.1)	35.8% (25.9-45.8)	32.8% (21.2-44.4)	44.0% (32.3-55.6)

Appendix Table 4.6b. Sexually Transmitted Infections Testing Among Sexually Active[a] People Living With Diagnosed HIV, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015 %[b] (95% CI)[c]	2016 %[b] (95% CI)[c]	2017 %[b] (95% CI)[c]	2018 %[b] (95% CI)[c]	2019 %[b] (95% CI)[c]
Gonorrhea, Chlamydia, and Syphilis					
Yes, received all 3 tests	42.2% (30.2-54.2)	30.2% (21.5-38.9)	37.5% (27.8-47.3)	53.0% (40.5-65.5)	42.3% (31.7-52.9)
Fewer than 3 tests documented	57.8% (45.8-69.8)	39.8% (61.1-78.5)	62.5% (52.7-72.2)	47.0% (34.5-59.5)	57.7% (47.1-68.3)
TOTAL	**105**	**125**	**138**	**104**	**127**

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody; EIA, enzyme immunoassay; ELISA, enzyme-linked immunoassay; FTA-ABS, fluorescent treponemal antibody absorbed; MHA-TP, microhemagglutination assay for antibody to Treponema pallidum; NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; TP-PA, T. pallidum particle agglutination; TPHA, T. pallidum hemagglutination assay; VDRL, Venereal Disease Research Laboratory. Note: Information on laboratory testing for sexually transmitted diseases was based on medical record abstraction. [a] Sexual activity was reported in the interview component of the Medical Monitoring Project and was defined as anal or vaginal intercourse. [b] Percentages are weighted percentages. [c] CIs incorporate weighted percentages. [d] Testing for Neisseria gonorrhoeae was defined as documentation of a result from culture, gram stain, EIA, NAAT, or nucleic acid probe. [e] Chlamydia trachomatis testing was defined as a result from culture, DFA, EIA or ELISA, NAAT, or nucleic acid probe. [f] Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy.

Appendix Table 4.7. Emergency Department/Urgent Care Clinic Use and Hospital Admission, by Cycle Year - Medical Monitoring Project, CA

	2015 %[a] (95% CI)[b]	2016 %[a] (95% CI)[b]	2017 %[a] (95% CI)[b]	2018 %[a] (95% CI)[b]	2019 %[a] (95% CI)[b]
Number of Visits to Emergency Department					
0 visits	68.8% (60.8-76.7)	65.1% (58.0-72.3)	60.6% (53.1-68.1)	36.1% (55.1-71.1)	64.8% (57.1-72.4)
1 visit	17.3% (11.2-23.5)	21.9% (15.5-28.4)	22.4% (16.1-28.6)	18.8% (12.7-24.9)	18.5% (11.7-25.2)
2–4 visits	10.7% (5.2-16.2)	9.5% (5.6-13.5)	14.4% (8.7-20.2)	14.4%* (8.3-20.6)	14.6% (9.9-19.3)
≥5 visits	3.2%* (0.4-6.0)	3.4%* (1.2-5.6)	2.6%* (0.0-5.3)	3.7%* (1.1-6.3)	2.2%* (0.2-4.3)

Appendix Table 4.7. Emergency Department/Urgent Care Clinic Use and Hospital Admission, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Number of Hospital Admissions					
0 admissions	84.6% (78.1-91.1)	86.6% (81.9-91.4)	80.6% (74.6-86.6)	85.1% (79.8-90.3)	82.4% (76.3-88.5)
1 admission	8.4% (3.9-12.9)	8.9% (4.9-13.0)	11.4% (7.0-15.9)	8.1%* (3.9-12.2)	12.9%* (7.2-18.5)
2–4 admissions	5.2% (0.7-9.8)*	3.7% (1.3-6.1)*	6.1% (2.3-9.9)*	4.9%* (2.0-7.7)	4.3%* (1.7-7.0)
≥5 admissions	1.8%* (0.0-4.3)	0.7%* (0.0-1.7)	1.9%* (0.0-4.6)	2.0%* (0.0-4.0)	0.4%* (0.0-1.2)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 4.8. Gynecological Care and Reproductive Health Among Women, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Papanicolaou (Pap) Test, Past 12 Months					
Yes	78.3%* (60.5-96.0)	70.2%* (50.6-89.8)	72.3% (57.3-87.3)	62.2%* (39.4-85.1)	85.8%* (72.4-99.3)
No	21.7%* (4.0-39.5)	29.8%* (10.2-49.4)	27.7% (12.7-42.7)	37.8%* (14.9-60.6)	14.2%* (0.7-27.6)
Pregnant Since HIV Diagnosis					
Yes	20.2%* (2.6-37.9)	47.0%* (26.7-67.4)	31.4%* (16.4-46.4)	39.1%* (18.5-59.7)	18.3%* (3.0-33.6)
No	79.8%* (62.1-97.4)	53.0%* (32.6-73.3)	68.6%* (53.6-83.6)	60.9%* (40.3-81.5)	81.7%* (66.4-97.0)
TOTAL	**29**	**29**	**40**	**36**	**27**

Abbreviation: CI, confidence interval. Note: Measures are self-reported. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 5.1. Depression and Anxiety, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Moderate or Severe Depression (PHQ-8 score ≥10)					
Yes	19.0% (12.4-25.7)	20.2% (14.0-26.4)	14.7% (9.8-19.6)	12.8%* (7.6-18.0)	16.8% (10.1-23.5)
No	81.0% (74.3-87.6)	79.8% (73.6-86.0)	85.3% (80.4-90.2)	87.2% (82.0-92.4)	83.2% (76.5-89.9)
Anxiety[c]					
No anxiety	78.9% (71.6-86.2)	71.6% (64.6-78.6)	80.1% (74.5-85.7)	81.8% (75.9-87.6)	78.1% (71.1-85.0)
Mild anxiety	7.8%* (2.5-13.2)	11.1% (6.0-16.3)	6.2% (2.6-9.9)	4.9%* (1.8-7.9)	5.9%* (1.0-10.8)
Moderate anxiety	8.3% (3.5-13.1)	8.9% (4.7-13.1)	8.4% (4.7-12.1)	6.6%* (2.7-10.5)	10.1% (5.2-15.0)
Severe anxiety	4.9%* (1.7-8.1)	8.4% (4.0-12.8)	5.3% (2.5-8.0)	6.8%* (3.2-10.3)	6.0%* (2.9-9.1)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD-7, Generalized Anxiety Disorder 7-item Scale; PHQ-8, Patient Health Questionnaire. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Responses to the GAD–7 were used to define "mild anxiety", "moderate anxiety" and "severe anxiety," according to criteria from the DSM-IV. "Severe anxiety" was defined as having a score of ≥15; "moderate anxiety" was defined as having a score of 10–14; and "mild anxiety" was defined as having a score of 5–9.

Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Smoked ≥100 Cigarettes (lifetime)					
Yes	57.5% (48.4-66.5)	57.9% (50.5-65.2)	60.0% (52.7-67.4)	49.2% (40.8-57.7)	52.2% (44.1-60.4)
No	42.5% (33.5-51.6)	42.1% (34.8-49.5)	40.0% (32.6-47.3)	50.8% (42.3-59.2)	47.8% (39.6-55.9)

Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Cigarette Smoking Status					
Current smoker	28.8% (20.6-36.9)	26.8% (20.2-33.3)	27.2% (20.3-34.1)	27.0% (19.2-34.8)	28.0% (20.4-35.6)
Former smoker	28.7% (20.8-36.6)	31.1% (24.0-38.2)	32.8% (25.7-39.9)	22.2% (16.0-28.5)	24.2% (17.4-31.0)
Never smoked	42.5% (33.5-51.6)	42.1% (34.8-49.5)	40.0% (32.6-47.3)	50.8% (42.3-59.2)	47.8% (39.6-55.9)
Frequency of Current Cigarette Smoking					
Less than monthly	4.7%* (0.0-9.4)	2.0%* (0.3-3.6)	1.6%* (0.0-3.1)	1.5%* (0.0-3.2)	2.3%* (0.4-4.1)
Monthly	0.7%* (0.0-2.1)	0.3%* (0.0-0.9)	2.3%* (0.0-4.6)	4.1%* (0.0-9.0)	4.7%* (0.0-9.5)
Weekly	5.1%* (1.1-9.1)	3.4%* (1.0-5.7)	6.4% (2.9-9.9)	4.7%* (1.0-8.3)	2.8%* (0.7-4.9)
Daily	18.2% (11.6-24.8)	21.1% (14.9-27.3)	17.0% (10.9-23.1)	16.8% (10.7-22.9)	18.3% (11.8-24.7)
Never	71.2% (63.1-79.4)	73.2% (66.7-79.8)	72.8% (65.9-79.7)	73.0% (65.2-80.8)	72.0% (64.4-79.6)
Smoked ≥50 Cigars, Cigarillos, or Little Filtered Cigars (lifetime)					
Yes	8.7% (4.3-13.1)	10.7% (6.1-15.4)	14.0% (9.2-18.9)	11.8%* (6.5-17.2)	13.4%* (7.6-19.3)
No	91.3% (86.9-95.7)	89.3% (84.6-93.9)	86.0% (81.1-90.8)	88.2% (82.8-93.5)	86.6% (80.7-92.4)
Cigars, Cigarillos, or Little Filtered Cigars Smoking Status					
Current smoker	4.3%* (1.0-7.6)	4.2%* (1.6-6.7)	6.1% (3.1-9.1)	6.1%* (2.1-10.1)	6.9%* (2.6-11.3)
Former smoker	4.4%* (1.5-7.4)	6.6%* (2.5-10.7)	8.0% (4.0-11.9)	5.7%* (1.9-9.6)	6.5%* (2.2-10.8)
Never smoked	91.3% (86.9-95.7)	89.3% (84.6-93.9)	86.0% (81.1-90.8)	88.2% (82.8-93.5)	86.6% (80.7-92.4)

Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Frequency of Current Cigars, Cigarillos, or Little Filtered Cigars Smoking					
Rarely	1.4%* (0.0-3.2)	1.2%* (0.0-2.5)	4.0%* (1.5-6.5)	3.7%* (0.4-7.1)	3.8%* (0.0-7.6)
Some days	0.8%* (0.0-2.3)	0.4%* (0.0-1.3)	0.7%* (0.0-1.7)	0.6%* (0.0-1.7)	2.0%* (0.2-3.7)
Daily	2.1%* (0.0-4.5)	2.5%* (0.5-4.6)	1.4%* (0.0-2.8)	1.8%* (0.0-3.6)	1.2%* (0.0-2.5)
Never	95.7% (92.4-99.0)	95.8% (93.3-98.4)	93.9% (90.9-96.9)	93.9% (89.9-97.9)	93.1% (88.7-97.4)
Electronic Cigarette Smoking Status					
Used electronic cigarettes in the past 30 days	3.3%* (0.0-6.7)	7.6% (3.1-12.1)	5.2%* (1.6-8.9)	7.6%* (2.2-13.0)	10.8%* (4.7-16.9)
Used electronic cigarettes, but not in the past 30 days	19.6% (13.0-26.1)	26.2% (19.6-32.7)	21.5% (15.0-28.0)	23.6% (16.4-30.8)	22.9% (16.0-29.8)
Never used electronic cigarettes	77.1% (70.0-84.2)	66.2% (59.0-73.4)	73.3% (66.3-80.2)	68.8% (60.7-76.9)	66.2% (58.2-74.3)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 5.3. Alcohol Use, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Any Alcohol Use[c]					
Yes	67.2% (58.8-75.5)	73.6% (67.0-80.2)	62.5% (55.1-69.9)	66.9% (59.2-74.6)	60.9% (52.8-69.1)
No	32.8% (24.5-41.2)	26.4% (19.8-33.0)	37.5% (30.1-44.9)	33.1% (25.4-40.8)	39.1% (30.9-47.2)

Appendix Table 5.3. Alcohol Use, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Frequency of Alcohol Use					
Daily	10.0% (4.1-15.9)	7.3% (3.9-10.7)	8.8% (4.3-13.3)	8.1%* (4.1-12.1)	4.8%* (2.0-7.6)
Weekly	16.7% (10.1-23.3)	33.3% (26.0-40.7)	17.9% (12.0-23.9)	26.1% (18.3-33.9)	19.4% (13.4-25.4)
Monthly	14.5% (8.3-20.7)	14.1% (8.9-19.4)	16.8% (11.3-22.3)	14.5%* (8.1-20.9)	15.2% (9.8-20.6)
Less than monthly	26.0% (17.9-34.0)	18.8% (13.4-24.2)	18.9% (13.3-24.6)	18.2% (12.0-24.4)	21.5% (14.5-28.5)
Never	32.8% (24.5-41.2)	26.4% (19.8-33.0)	37.5% (30.1-44.9)	33.1% (25.4-40.8)	39.1% (30.9-47.2)
Binge Drinking, Past 30 Days[d]					
Yes	16.6% (9.9-23.4)	16.2% (10.6-21.8)	11.6% (6.5-16.6)	15.0%* (9.4-20.7)	16.9% (11.3-22.5)
No	83.4% (76.6-90.1)	83.8% (78.2-89.4)	88.4% (83.4-93.5)	85.0% (79.3-90.6)	83.1% (77.5-88.7)
TOTAL	176	221	229	192	218

Abbreviation: CI, confidence interval. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Persons who drank at least 1 alcoholic beverage during the 12 months before the interview. Alcoholic beverage was defined as a 12-ounce beer, 5-ounce glass of wine, or 1.5-ounce shot of liquor. [d] Persons who drank ≥5 alcoholic beverages in a single sitting (≥4 for women) during the 30 days before the interview.

Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Use of Any Non-Injection Drugs[c]					
Yes	33.8% (25.0-42.6)	29.8% (23.0-36.6)	37.6% (30.2-45.0)	50.1% (41.7-58.6)	40.2% (32.2-48.3)
No	66.2% (57.4-75.0)	70.2% (63.4-77.0)	62.4% (55.0-69.8)	49.9% (41.4-58.3)	59.8% (51.7-67.8)

Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2019 (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Non-Injection Drugs Used[c]:					
Marijuana					
Yes	30.1% (21.5-38.7)	25.2% (18.8-31.5)	34.7% (27.4-42.0)	40.3% (31.9-48.7)	36.4% (28.4-44.4)
No	69.9% (61.3-78.5)	74.8% (68.5-81.2)	65.3% (58.0-72.6)	59.7% (51.3-68.1)	63.6% (55.6-71.6)
Crack					
Yes	1.4%* (0.0-3.2)	1.0%* (0.0-2.2)	1.4%* (0.0-2.8)	1.5%* (0.0-3.1)	1.7%* (0.0-3.3)
No	98.6% (96.8-100.0)	99.0% (97.8-100.0)	98.6% (97.2-100.0)	98.5% (96.9-100.0)	98.3% (96.7-100.0)
Cocaine that is smoked or snorted					
Yes	7.2%* (1.4-13.0)	4.1%* (1.0-7.2)	6.8% (2.8-10.7)	6.8%* (1.8-11.7)	7.0%* (3.8-10.3)
No	92.8% (87.0-98.6)	95.9% (92.8-99.0)	93.2% (89.3-97.2)	93.2% (88.3-98.2)	93.0% (89.7-96.2)
Methamphetamine (e.g., crystal meth, tina, crank, ice)					
Yes	14.3% (7.1-21.4)	12.8% (7.8-17.8)	10.7% (5.8-15.6)	16.3%* (9.9-22.7)	9.3%* (5.5-13.0)
No	85.7% (78.6-92.9)	87.2% (82.2-92.2)	89.3% (84.4-94.2)	83.7% (77.3-90.1)	90.7% (87.0-94.5)
Amphetamine (e.g., speed, bennies, uppers)					
Yes	6.4%* (1.6-11.3)	2.0%* (0.2-3.7)	2.1%* (0.0-4.3)	5.5%* (1.4-9.6)	5.2%* (2.3-8.0)
No	93.6% (88.7-98.4)	98.0% (96.3-99.8)	97.9% (95.7-100.0)	94.5% (90.4-98.6)	94.8% (92.0-97.7)
Club drugs (e.g., Ecstasy or X, ketamine or Special K, GHB or Liquid Ecstasy)					
Yes	6.5%* (2.2-10.7)	7.0%* (2.8-11.2)	2.9%* (0.8-5.0)	8.4%* (3.6-13.2)	7.3%* (4.0-10.6)
No	93.5% (89.3-97.8)	93.0% (88.8-97.2)	97.1% (95.0-99.2)	91.6% (86.8-96.4)	92.7% (89.4-96.0)

Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Amyl nitrite (poppers)					
Yes	9.5% (4.0-15.0)	11.3% (6.5-16.1)	9.2% (5.0-13.4)	13.6%* (7.3-19.8)	13.0% (7.8-18.1)
No	90.5% (85.0-96.0)	88.7% (83.9-93.5)	90.8% (86.6-95.0)	86.4% (80.2-92.7)	87.0% (81.9-92.2)
Prescription opioids (e.g., oxycodone, hydrocodone, Vicodin, Percocet)[e]					
Yes	5.0%* (1.5-8.5)	2.8%* (0.6-4.9)	1.8%* (0.2-3.3)	3.8%* (1.0-6.6)	5.9%* (1.7-10.2)
No	95.0% (91.5-98.5)	97.2% (95.1-99.4)	98.2% (96.7-99.8)	96.2% (93.4-99.0)	94.1% (89.8-98.3)
Prescription tranquilizers (e.g., Valium, Ativan, Xanax, downers, nerve pills)[e]					
Yes	0.5%* (0.0-1.4)	0.9%* (0.0-2.1)	3.0%* (0.8-5.2)	4.1%* (0.9-7.2)	5.9%* (1.7-10.1)
No	99.5% (98.6-100.0)	99.1% (97.9-100.0)	97.0% (94.8-99.2)	95.9% (92.8-99.1)	94.1% (89.9-98.3)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; GHB, gamma hydroxybutyrate. Note: Persons could report taking more than 1 noninjection drug. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Includes all drugs that were not injected (i.e., administered by any route other than injection), including legal drugs that were not used for medical purposes. [d] Not prescribed, or prescribed but taken more than directed.

Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Use of Any Injection Drugs					
Yes	3.8%* (0.2-7.3)	4.3% (1.8-6.9)	2.9%* (0.7-5.1)	5.4%* (1.5-9.2)	3.7%* (1.3-6.2)
No	96.2% (92.7-99.8)	95.7% (93.1-98.2)	97.1% (94.9-99.3)	94.6% (90.8-98.5)	96.3% (93.8-98.7)

Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Injection Drugs Used:					
Cocaine					
Yes	0.0%	0.0%	0.4%* (0.0-1.3)	0.6%* (0.0-1.7)	0.0%
No	100.0%	100.0%	99.6% (98.7-100.0)	99.4% (98.3-100.0)	100.0%
Heroin					
Yes	1.4%* (0.0-4.2)	0.6%* (0.0-1.4)	0.9%* (0.0-2.1)	0.4%* (0.0-1.3)	0.0%
No	98.6% (95.8-100.0)	99.4% (98.6-100.0)	99.1% (97.9-100.0)	99.6% (98.7-100.0)	100.0%
Heroin and cocaine (speedball)					
Yes	0.0%	0.1%* (0.0-0.3)	0.4%* (0.0-1.3)	0.4%* (0.0-1.3)	0.0%
No	100.0%	99.9% (99.7-100.0)	99.6% (98.7-100.0)	99.6% (98.7-100.0)	100.0%
Methamphetamine (e.g., crystal meth, tina, crank, ice)					
Yes	3.4%* (0.0-6.9)	3.9%* (1.5-6.3)	2.5%* (0.5-4.4)	4.8%* (1.1-8.5)	3.7%* (1.3-6.2)
No	96.6% (93.1-100.0)	96.1% (93.7-98.5)	97.5% (95.6-99.5)	95.2% (91.5-98.9)	96.3% (93.8-98.7)
Amphetamine (e.g., speed, bennies, uppers)					
Yes	0.3%* (0.0-1.0)	0.9%* (0.0-2.0)	1.6%* (0.0-3.2)	0.4%* (0.0-1.2)	0.7%* (0.0-1.6)
No	99.7% (99.0-100.0)	99.1% (98.0-100.0)	98.4% (96.8-100.0)	99.6% (98.8-100.0)	99.3% (98.4-100.0)

Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Prescription opioids (e.g., OxyContin, oxycodone, hydrocodone)					
Yes	1.4%* (0.0-4.2)	0.5%* (0.0-1.5)	0.0%	0.0%	0.0%
No	98.6% (95.8-100.0)	99.5% (98.5-100.0)	100.0%	100.0%	100.0%
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviation: CI, confidence interval. Note: Persons could report taking more than 1 injection drug. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 6.1a. Sexual Behavior Among Cisgender Men, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Anal Sex With Men:					
Receptive					
Yes	44.0% (33.9-54.1)	42.4% (34.3-50.4)	48.7% (40.2-57.2)	38.6% (29.4-47.7)	38.4% (29.7-47.1)
No	56.0% (45.9-66.1)	57.6% (49.6-65.6)	51.3% (42.8-59.8)	61.4% (52.3-70.6)	61.6% (52.9-70.3)
Insertive					
Yes	41.1% (31.1-51.1)	42.8% (34.8-50.9)	44.4% (35.9-52.8)	36.5% (27.1-45.9)	41.8% (32.9-50.7)
No	58.9% (48.9-68.9)	57.2% (49.1-65.2)	55.6% (47.2-64.1)	63.5% (54.1-72.9)	58.2% (49.3-67.1)
Engaged in Anal Sex With Women					
Yes	0.2%* (0.0-0.5)	1.7%* (0.0-3.5)	3.1%* (0.6-5.6)	1.9%* (0.1-3.7)	2.3%* (0.3-4.4)
No	99.8% (99.5-100.0)	98.3% (96.5-100.0)	96.9% (94.4-99.4)	98.1% (96.3-99.9)	97.7% (95.6-99.7)

Appendix Table 6.1a. Sexual Behavior Among Cisgender Men, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Vaginal Sex					
Yes	15.0% (8.0-22.1)	6.8% (3.3-10.4)	9.9% (5.5-14.2)	14.4%* (8.6-20.2)	11.3%* (5.5-17.0)
No	85.0% (77.9-92.0)	93.2% (89.6-96.7)	90.1% (85.8-94.5)	85.6% (79.8-91.4)	88.7% (83.0-94.5)
Engaged in Vaginal or Anal Sex					
Yes	65.2% (56.0-74.3)	58.9% (51.0-66.8)	64.3% (56.4-72.2)	61.2% (52.3-70.2)	61.8% (53.3-70.4)
No	34.8% (25.7-44.0)	41.1% (33.2-49.0)	35.7% (27.8-43.6)	38.8% (29.8-47.7)	38.2% (29.6-46.7)
TOTAL	**147**	**192**	**185**	**152**	**186**

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 6.1b. Sexual Behavior Among Cisgender Women, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Anal Sex With Men					
Yes	4.9%* (0.0-14.2)	7.3%* (0.0-19.7)	9.3%* (0.3-18.2)	4.7%* (0.0-10.1)	3.7%* (0.0-10.9)
No	95.1%* (85.8-100.0)	92.7%* (82.1-100.0)	90.7%* (81.8-99.7)	95.3% (89.9-100.0)	96.3%* (89.1-100.0)
Engaged in Vaginal Sex					
Yes	55.9%* (35.8-76.1)	57.3%* (36.5-78.1)	45.7%* (28.6-62.8)	39.7%* (19.3-60.2)	61.9%* (41.4-82.3)
No	44.1%* (23.9-64.2)	42.7%* (21.9-63.5)	54.3%* (37.2-71.4)	60.3%* (39.8-80.7)	38.1%* (17.7-58.6)

Appendix Table 6.1b. Sexual Behavior Among Cisgender Women, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Vaginal or Anal Sex					
Yes	55.9%* (35.8-76.1)	57.3%* (36.5-78.1)	45.7%* (28.6-62.8)	39.7%* (19.3-60.2)	61.9%* (41.4-82.3)
No	44.1%* (23.9-64.2)	42.7%* (21.9-63.5)	54.3%* (37.2-71.4)	60.3%* (39.8-80.7)	38.1%* (17.7-58.6)
TOTAL	**29**	**29**	**40**	**36**	**27**

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 6.3a. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex With Men (MSM), by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Any High-Risk Sex[c]					
Yes	5.6%* (0.3-10.9)	11.0%* (4.1-17.8)	8.0%* (2.0-13.9)	8.6%* (3.4-13.7)	13.2%* (5.4-21.0)
No	94.4% (89.1-99.7)	89.0% (82.2-95.9)	92.0% (86.1-98.0)	91.4% (86.3-96.6)	86.8% (79.0-94.6)
Engaged in Any High-Risk Sex (among sexually active persons)[c]					
Yes	8.0%* (0.5-15.6)	17.0%* (6.9-27.2)	11.4%* (3.0-19.7)	13.5%* (5.5-21.5)	20.9%* (9.3-32.5)
No	92.0% (84.4-99.5)	83.0% (72.8-93.1)	88.6% (80.3-97.0)	86.5% (78.5-94.5)	79.1% (67.5-90.7)
Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner:					
Sex while sustainably virally suppressed[d]					
Yes	67.1% (53.4-80.9)	65.4% (54.4-76.4)	71.3% (60.3-82.2)	50.9% (36.9-64.9)	61.2% (48.1-74.2)
No	32.9% (19.1-46.6)	34.6% (23.6-45.6)	28.7% (17.8-39.7)	49.1% (35.1-63.1)	38.8% (25.8-51.9)

Appendix Table 6.3a. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex With Men (MSM), by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Condom-protected sex[e]					
Yes	49.1% (34.3-64.0)	62.0% (50.6-73.3)	58.5% (46.6-70.3)	61.9% (48.2-75.6)	54.1% (41.3-66.9)
No	50.9% (36.0-65.7)	38.0% (26.7-49.4)	41.5% (29.7-53.4)	38.1%* (24.4-51.8)	45.9% (33.1-58.7)
Condomless sex with a partner on PrEP[f]					
Yes	11.3%* (2.1-20.5)	13.7% (6.2-21.2)	14.6% (6.5-22.8)	17.7% (8.4-27.0)	23.7% (14.0-33.5)
No	88.7% (79.5-97.9)	86.3% (78.8-93.8)	85.4% (77.2-93.5)	82.3% (73.0-91.6)	76.3% (66.5-86.0)
Sex with an HIV positive partner[g]					
Yes	69.5% (56.8-82.3)	67.9% (57.6-78.2)	44.7% (33.2-56.3)	55.6% (41.9-69.4)	52.5% (40.0-65.0)
No	30.5% (17.7-43.2)	32.1% (21.8-42.4)	55.3% (43.7-66.8)	44.4% (30.6-58.1)	47.5% (35.0-60.0)
TOTAL	**109**	**158**	**147**	**111**	**151**

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. [d] HIV viral load <200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. [e] Condoms were consistently used with at least 1 vaginal or anal sex partner. [f] At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. [g] Sex with at least 1 HIV-positive partner.

Appendix Table 6.3b. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex Only With Women (MSW), by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Any High-Risk Sex[c]					
Yes	3.1%* (0.0-9.2)	0.8%* (0.0-2.5)	8.9%* (0.0-18.7)	15.9%* (3.0-28.7)	6.6%* (0.0-15.6)
No	91.6% (90.8-100.0)	99.2% (97.5-100.0)	91.1% (81.3-100.0)	84.1%* (71.3-97.0)	93.4%* (84.4-100.0)
Engaged in Any High-Risk Sex (among sexually active persons)[c]					
Yes	5.8%* (0.0-17.1)	2.2%* (0.0-6.7)	25.0%* (0.1-50.0)	25.9%* (6.2-45.6)	10.4%* (0.0-24.6)
No	94.2% (82.9-100.0)	97.8% (93.3-100.0)	75.0%* (50.0-99.9)	74.1%* (54.4-93.8)	89.6%* (75.4-100.0)
Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner:					
Sex while sustainably virally suppressed[d]					
Yes	47.1%* (21.0-73.2)	49.3%* (19.4-79.2)	52.0%* (24.1-79.9)	48.9%* (26.1-71.6)	61.0%* (34.4-87.6)
No	52.9%* (26.8-79.0)	50.7%* (20.8-80.6)	48.0% (20.1-75.9)	51.1%* (28.4-73.9)	39.0%* (12.4-65.6)
Condom-protected sex[e]					
Yes	69.3%* (41.3-97.2)	75.6%* (50.7-100.0)	72.9%* (47.6-98.1)	53.9%* (31.3-76.5)	51.4%* (21.0-81.7)
No	30.7%* (2.8-58.7)	24.4%* (0.0-49.3)	27.1%* (1.9-52.4)	46.1%* (23.5-68.7)	48.6%* (18.3-79.0)
Condomless sex with a partner on PrEP[f]					
Yes	0.0%	11.7%* (0.0-29.9)	0.0%	10.4%* (0.0-24.5)	0.0%
No	100.0%	88.3% (70.1-100.0)	100.0%	89.6%* (75.5-100.0)	100.0%

Appendix Table 6.3b. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex Only With Women (MSW), by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Sex with an HIV positive partner[g]					
Yes	35.9%* (8.3-63.6)	23.4%* (0.0-49.0)	15.9%* (0.0-36.3)	11.7%* (0.0-27.1)	38.8%* (5.7-71.8)
No	64.1%* (36.4-91.7)	76.6%* (51.0-100.0)	84.1%* (63.7-100.0)	88.3%* (72.9-100.0)	61.2%* (28.2-94.3)
TOTAL	**34**	**28**	**33**	**33**	**28**

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. [d] HIV viral load <200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. [e] Condoms were consistently used with at least 1 vaginal or anal sex partner. [f] At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. [g] Sex with at least 1 HIV-positive partner.

Appendix Table 6.3c. Sexual Behavior During the 12 Months Before the Interview Among Women Who Had Sex With Men (WSM), by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Engaged in Any High-Risk Sex[c]					
Yes	0.6%* (0.0-1.7)	0.0%	2.4%* (0.0-7.2)	1.6%* (0.0-4.7)	0.0%
No	99.4% (98.3-100.0)	100.0%	97.6% (92.8-100.0)	98.4% (95.3-100.0)	100.0%
Engaged in Any High-Risk Sex (among sexually active persons)[c]					
Yes	1.0%* (0.0-3.0)	0.0%	5.2%* (0.0-15.2)	3.9%* (0.0-11.5)	0.0%
No	99.0% (97.0-100.0)	100.0%	94.8% (84.8-100.0)	96.1%* (88.5-100.0)	100.0%

Appendix Table 6.3c. Sexual Behavior During the 12 Months Before the Interview Among Women Who Had Sex With Men (WSM), by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner:					
Sex while sustainably virally suppressed[d]					
Yes	63.7%* (33.0-94.3)	96.0% (88.2-100.0)	84.6%* (68.3-100.0)	54.8%* (24.8-84.8)	94.4%* (83.4-100.0)
No	36.3%* (5.7-67.0)	4.0%* (0.0-11.8)	15.4%* (0.0-31.1)	45.2%* (15.2-75.2)	5.6%* (0.0-16.6)
Condom-protected sex[e]					
Yes	54.9%* (25.3-84.6)	34.1%* (6.7-61.4)	41.7%* (18.9-64.5)	73.5%* (45.9-100.0)	47.6%* (15.4-79.9)
No	45.1%* (15.4-74.7)	65.9%* (38.6-93.3)	58.3%* (35.5-81.1)	26.5%* (0.0-54.1)	52.4%* (20.1-84.6)
Condomless sex with a partner on PrEP[f]					
Yes	0.0%	0.0%	0.0%	0.0%	5.6%* (0.0-16.6)
No	100.0%	100.0%	100.0%	100.0%	94.4%* (83.4-100.0)
Sex with an HIV positive partner[g]					
Yes	62.6%* (33.6-91.6)	16.4%* (0.1-32.8)	28.1%* (6.1-50.2)	31.7%* (3.4-60.0)	17.7%* (0.0-37.4)
No	37.4%* (8.4-66.4)	83.6%* (67.2-99.9)	71.9%* (49.8-93.9)	68.3%* (40.0-96.6)	82.3%* (62.6-100.0)
TOTAL	**29**	**28**	**38**	**35**	**25**

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. [d] HIV viral load <200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. [e] Condoms were consistently used with at least 1 vaginal or anal sex partner. [f] At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. [g] Sex with at least 1 HIV-positive partner.

Appendix Table 7.1. Intimate Partner Violence and Sexual Violence, by Cycle Year - Medical Monitoring Project, CA

	2015 %[a] (95% CI)[b]	2016 %[a] (95% CI)[b]	2017 %[a] (95% CI)[b]	2018 %[a] (95% CI)[b]	2019 %[a] (95% CI)[b]
Was ever slapped, punched, shoved, kicked, choked or otherwise physically hurt by a romantic or sexual partner					
Yes	28.0% (19.7-36.3)	24.2% (17.8-30.7)	30.1% (22.8-37.3)	25.4% (18.6-32.2)	32.5% (24.5-40.6)
No	72.0% (63.7-80.3)	75.8% (69.3-82.2)	69.9% (62.7-77.2)	74.6% (67.8-81.4)	67.5% (59.4-75.5)
Was slapped, punched, shoved, kicked, choked or otherwise physically hurt by a romantic or sexual partner, past 12 months					
Yes	5.0%* (0.3-9.7)	3.9%* (0.8-7.0)	5.3%* (1.6-9.1)	2.3%* (0.1-4.5)	5.0%* (0.1-9.9)
No	95.0% (90.3-99.7)	96.1% (93.0-99.2)	94.7% (90.9-98.4)	97.7% (95.5-99.9)	95.0% (90.1-99.9)
Was ever threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex					
Yes	15.8% (10.2-21.3)	16.5% (11.0-22.1)	19.5% (13.1-25.9)	15.5% (10.1-20.9)	23.7% (17.0-30.4)
No	84.2% (78.7-89.8)	83.5% (77.9-89.0)	80.5% (74.1-86.9)	84.5% (79.1-89.9)	76.3% (69.9-83.0)
Was threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex, past 12 months					
Yes	1.2%* (0.0-2.9)	2.8%* (0.0-5.6)	1.7%* (0.1-3.2)	0.6%* (0.0-1.8)	1.9%* (0.0-4.8)
No	98.8% (97.1-100.0)	97.2% (94.4-100.0)	98.3% (96.8-99.9)	99.4% (98.3-100.0)	98.1% (95.2-100.0)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Dental Care					
Needed, but did not receive service	24.0% (16.5-31.4)	20.8% (14.6-27.1)	21.7% (15.6-27.8)	24.9% (17.4-32.5)	18.9% (12.7-25.1)
Received service	59.3% (50.6-68.0)	65.2% (58.0-72.4)	63.8% (56.5-71.0)	59.1% (50.9-67.4)	70.6% (63.3-77.9)
Did not need, did not receive service	16.8% (10.3-23.2)	14.0% (8.7-19.3)	14.6% (9.0-20.1)	16.0% (10.2-21.7)	10.5%* (5.6-15.4)
SNAP or WIC					
Needed, but did not receive service	14.9% (8.3-21.4)	11.4% (6.8-16.0)	9.1% (4.7-13.4)	9.5%* (3.8-15.1)	8.8%* (3.6-14.1)
Received service	15.8% (9.4-22.3)	25.1% (18.5-31.8)	17.2% (11.7-22.7)	16.4% (10.9-21.9)	27.1% (19.7-34.5)
Did not need, did not receive service	69.3% (61.0-77.6)	63.5% (56.2-70.7)	73.7% (67.2-80.3)	74.1% (66.9-81.4)	64.0% (56.0-72.1)
Transportation Assistance					
Needed, but did not receive service	15.3% (9.0-21.6)	6.4% (3.2-9.6)	7.8%* (3.1-12.4)	10.4%* (4.9-15.9)	8.0%* (4.5-11.6)
Received service	15.6% (9.3-21.9)	16.5% (11.1-21.9)	18.0% (12.6-23.5)	20.5% (14.1-26.9)	21.0% (14.9-27.1)
Did not need, did not receive service	69.1% (61.0-77.2)	77.1% (71.1-83.1)	74.2% (67.6-80.8)	69.1% (61.4-76.8)	71.0% (64.2-77.8)
Mental Health Services					
Needed, but did not receive service	12.8% (7.0-18.5)	9.0% (4.1-13.9)	6.6% (3.5-9.7)	7.2%* (3.2-11.2)	10.9%* (6.0-15.9)
Received service	32.9% (24.4-41.3)	29.3% (22.8-35.8)	33.9% (26.8-41.0)	41.5% (33.2-49.8)	39.5% (31.4-47.6)
Did not need, did not receive service	54.4% (45.4-63.3)	61.6% (54.4-68.9)	59.5% (52.2-66.9)	51.4% (42.9-59.8)	49.6% (41.4-57.7)

Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA (cont.)

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Shelter or Housing Services					
Needed, but did not receive service	9.7% (4.7-14.6)	11.9% (6.8-17.1)	6.6% (3.6-9.6)	11.9%* (6.2-17.5)	4.5%* (1.8-7.1)
Received service	13.3% (8.0-18.7)	9.5% (5.3-13.7)	13.8% (9.4-18.3)	13.3%* (7.8-18.8)	17.9% (12.2-23.5)
Did not need, did not receive service	77.0% (70.1-84.0)	78.6% (72.4-84.8)	79.6% (74.4-84.9)	74.8% (67.5-82.1)	77.7% (71.6-83.8)
HIV Peer Group Support					
Needed, but did not receive service	10.5% (5.4-15.6)	9.9% (5.2-14.5)	7.7% (4.3-11.1)	6.0%* (2.7-9.3)	12.5%* (6.8-18.3)
Received service	7.4% (3.5-11.3)	8.5% (4.5-12.5)	14.0% (8.9-19.1)	14.3% (8.9-19.8)	12.3%* (6.3-18.3)
Did not need, did not receive service	82.1% (75.8-88.3)	81.7% (75.9-87.5)	78.3% (72.4-84.1)	79.7% (73.5-85.9)	75.2% (67.6-82.7)
Meal or Food Services[c]					
Needed, but did not receive service	8.8% (4.1-13.6)	9.0% (4.5-13.4)	6.6%* (2.6-10.7)	9.1%* (3.2-15.0)	6.3%* (2.3-10.3)
Received service	24.8% (17.3-32.4)	15.0% (9.7-20.3)	21.0% (15.1-26.9)	14.2% (9.0-13.4)	24.0% (17.2-30.9)
Did not need, did not receive service	66.4% (58.1-74.6)	76.1% (69.6-82.5)	72.4% (65.7-79.1)	76.7% (69.5-83.9)	69.7% (62.2-77.1)
HIV Case Management Services					
Needed, but did not receive service	6.9%* (2.8-11.1)	9.7% (5.1-14.2)	6.6% (3.0-10.2)	10.7%* (4.2-17.2)	3.8%* (0.0-7.6)
Received service	48.1% (39.1-57.0)	43.5% (36.2-50.8)	50.1% (42.5-57.7)	55.9% (47.4-64.4)	57.7% (49.8-65.7)
Did not need, did not receive service	45.0% (36.0-54.0)	46.8% (39.4-54.3)	43.3% (35.8-50.7)	33.4% (25.6-41.3)	38.5% (30.7-46.2)

Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Patient Navigation Services					
Needed, but did not receive service	5.2%* (2.1-8.3)	4.9% (2.1-7.6)	5.4% (2.5-8.4)	5.1%* (2.1-8.2)	3.7%* (1.3-6.1)
Received service	8.0% (3.5-12.4)	9.6% (5.6-13.6)	11.4% (6.7-16.0)	21.2% (14.2-28.2)	22.8% (16.1-29.6)
Did not need, did not receive service	86.8% (81.5-92.1)	85.6% (80.0-90.3)	83.2% (77.8-88.6)	73.6% (66.3-81.0)	73.5% (66.5-80.5)
Medicine Through ADAP					
Needed, but did not receive service	3.1%* (0.8-5.5)	7.4%* (2.8-12.0)	2.6%* (0.0-5.8)	5.5%* (0.6-10.3)	1.6%* (0.0-3.2)
Received service	52.9% (43.9-61.9)	47.5% (40.1-55.0)	46.2% (38.6-53.7)	46.5% (38.0-54.9)	46.2% (38.0-54.4)
Did not need, did not receive service	44.0% (35.0-53.0)	45.1% (37.7-52.5)	51.3% (43.6-58.9)	48.0% (39.6-56.5)	52.2% (44.0-60.5)
Drug or Alcohol Counseling or Treatment					
Needed, but did not receive service	3.5%* (0.1-7.0)	2.1%* (0.3-4.0)	3.3%* (0.5-6.2)	2.9%* (0.4-5.4)	1.6%* (0.0-3.2)
Received service	11.3% (5.1-17.4)	6.7% (3.4-10.0)	5.0%* (2.0-8.0)	12.1%* (6.4-17.9)	3.6%* (1.2-6.0)
Did not need, did not receive service	85.2% (78.4-92.0)	91.2% (87.5-94.9)	91.7% (87.6-95.8)	85.0% (78.8-91.1)	94.7% (91.9-97.6)
Professional HIV Medication Adherence Support Services					
Needed, but did not receive service	0.9%* (0.0-2.2)	1.7%* (0.0-3.4)	1.5%* (0.1-2.8)	0.5%* (0.0-1.5)	1.2%* (0.0-2.5)
Received service	29.1% (21.4-36.9)	26.3% (20.1-32.4)	27.8% (21.1-34.6)	41.3% (33.1-49.4)	35.2% (27.6-42.7)
Did not need, did not receive service	70.0% (62.1-77.8)	72.0% (65.7-78.3)	70.7% (63.9-77.6)	58.2% (50.1-66.4)	63.7% (56.1-71.3)

Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Domestic Violence Services					
Needed, but did not receive service	2.3%* (0.0-5.7)	1.0%* (0.0-2.3)	0.3%* (0.0-1.0)	0.4%* (0.0-1.2)	0.9%* (0.0-2.1)
Received service	0.0%	0.7%* (0.0-1.8)	0.4%* (0.0-1.3)	0.6%* (0.0-1.7)	1.3%* (0.0-2.8)
Did not need, did not receive service	97.7% (94.3-100.0)	98.3% (96.6-99.9)	99.2% (98.1-100.0)	99.0% (97.6-100.0)	97.8% (95.9-99.7)
TOTAL	**176**	**221**	**229**	**192**	**218**

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children. Note: Persons could report receiving or needing more than one service. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]
Dental Care					
Needed, but did not receive service	32.5%* (12.9-52.1)	38.8% (23.9-53.7)	27.7% (12.8-42.5)	38.8%* (22.2-55.3)	22.9%* (11.4-34.5)
Received service	56.5% (36.7-76.2)	51.4% (36.3-66.4)	57.9% (42.6-73.2)	46.2%* (30.6-61.7)	67.5% (53.9-81.0)
Did not need, did not receive service	11.1%* (1.3-20.8)	9.8%* (0.0-19.8)	14.4%* (3.4-25.4)	15.0%* (5.0-25.1)	9.6%* (2.0-17.2)
SNAP or WIC					
Needed, but did not receive service	26.1%* (9.4-42.8)	12.3%* (4.1-20.4)	13.4%* (3.9-22.9)	18.4%* (2.3-34.5)	8.1%* (1.0-15.2)
Received service	23.7%* (6.4-41.1)	41.6% (26.5-56.6)	29.7% (16.6-42.9)	25.9%* (13.3-38.5)	50.3%* (33.9-66.6)
Did not need, did not receive service	50.2% (30.5-70.0)	46.2% (31.2-61.2)	56.9% (42.3-71.4)	55.7%* (39.6-71.8)	41.6%* (26.0-57.2)
Transportation Assistance					
Needed, but did not receive service	45.9% (26.2-65.7)	10.3%* (2.3-18.2)	13.2%* (0.0-26.9)	23.0%* (6.5-39.5)	12.4%* (3.9-21.0)
Received service	18.8%* (3.1-34.5)	22.0%* (8.9-35.1)	24.8% (11.9-37.7)	28.8%* (15.8-41.8)	22.7%* (10.8-34.7)
Did not need, did not receive service	35.3% (16.6-54.0)	67.8% (53.7-81.9)	61.9% (46.5-77.3)	48.2%* (32.4-64.0)	64.8% (50.6-79.1)
Mental Health Services					
Needed, but did not receive service	18.4%* (5.6-31.3)	8.9%* (0.0-18.3)	9.9%* (1.2-18.6)	8.4%* (0.0-17.0)	16.2%* (6.3-26.1)
Received service	45.8% (26.1-65.6)	32.3% (18.9-45.8)	59.6% (45.4-73.7)	36.0%* (21.7-50.3)	47.1%* (30.8-63.5)
Did not need, did not receive service	35.7% (16.2-55.3)	58.8% (44.2-73.5)	30.5% (17.8-43.3)	55.6%* (40.2-71.0)	36.7%* (20.0-53.3)

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	% [a] (95% CI)[b]	%[a] (95% CI)[b]
Shelter or Housing Services					
Needed, but did not receive service	21.6%* (4.8-38.4)	27.9% (14.2-41.7)	12.3%* (3.7-20.9)	30.8%* (14.1-47.4)	6.3%* (0.1-12.4)
Received service	14.2%* (2.3-26.2)	15.7%* (4.9-26.6)	21.4% (10.3-32.4)	11.6%* (3.0-20.1)	14.6%* (4.6-24.6)
Did not need, did not receive service	64.1% (45.5-82.8)	56.4% (41.4-71.3)	66.4% (53.2-79.5)	57.7% (41.4-73.9)	79.1% (67.9-90.7)
HIV Peer Group Support					
Needed, but did not receive service	13.4%* (1.9-24.9)	14.4%* (3.5-25.3)	10.9%* (2.8-18.9)	12.1%* (2.5-21.8)	18.2%* (3.7-32.7)
Received service	18.8%* (5.2-32.3)	13.2%* (2.6-23.8)	22.5% (10.3-34.7)	15.1%* (5.0-25.2)	6.2%* (0.0-13.3)
Did not need, did not receive service	67.8% (50.9-84.8)	72.4% (58.6-86.2)	66.7% (53.1-80.3)	72.8% (59.6-86.0)	75.6% (60.4-90.8)
Meal or Food Services[c]					
Needed, but did not receive service	22.3%* (6.3-38.3)	14.0%* (3.2-24.8)	15.6%* (4.8-26.5)	18.7%* (2.3-35.1)	4.4%* (0.0-9.5)
Received service	32.5% (14.5-50.5)	12.9%* (2.7-23.1)	25.5% (13.7-37.3)	18.5%* (7.8-29.1)	30.3%* (14.4-46.1)
Did not need, did not receive service	45.2% (25.4-65.1)	73.1% (59.5-86.7)	58.9% (44.6-73.2)	62.8% (46.5-79.2)	65.3% (49.3-81.3)
HIV Case Management Services					
Needed, but did not receive service	20.6%* (5.0-36.2)	16.3%* (3.9-28.8)	15.7%* (5.0-26.4)	21.1%* (4.5-37.7)	4.4%* (0.0-9.5)
Received service	44.9% (25.1-64.6)	43.6% (29.3-57.9)	48.7% (33.7-63.6)	56.6% (40.2-73.0)	53.2%* (36.9-69.5)
Did not need, did not receive service	34.6% (15.8-53.3)	40.1% (24.8-55.4)	35.7% (22.0-49.3)	22.3%* (9.7-34.9)	42.4%* (26.3-58.5)

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015 %[a] (95% CI)[b]	2016 %[a] (95% CI)[b]	2017 %[a] (95% CI)[b]	2018 %[a] (95% CI)[b]	2019 %[a] (95% CI)[b]
Patient Navigation Services					
Needed, but did not receive service	4.4%* (0.0-10.4)	5.1%* (0.0-11.1)	18.6%* (7.2-30.1)	13.7%* (3.4-24.0)	4.3%* (0.0-9.2)
Received service	7.6%* (0.3-14.8)	18.3% (8.2-28.4)	19.5%* (4.7-34.3)	28.8%* (15.5-42.1)	20.0%* (4.7-35.4)
Did not need, did not receive service	88.1% (78.7-97.5)	76.6% (65.3-88.0)	61.9% (46.4-77.3)	57.5%* (42.2-72.8)	75.7% (60.1-91.2)
Medicine Through ADAP					
Needed, but did not receive service	5.3%* (0.0-12.5)	13.9%* (1.5-26.3)	2.0%* (0.0-5.5)	16.9%* (0.0-33.8)	1.4%* (0.0-4.2)
Received service	52.5% (32.3-72.7)	44.2% (29.5-59.0)	66.6% (53.2-80.0)	37.2%* (22.7-51.7)	37.3%* (21.3-53.4)
Did not need, did not receive service	42.2% (22.3-62.2)	41.9% (27.2-56.7)	31.4% (18.2-44.5)	45.9%* (30.1-61.7)	61.3% (45.2-77.4)
Drug or Alcohol Counseling or Treatment					
Needed, but did not receive service	4.9%* (0.0-12.1)	3.2%* (0.0-7.6)	4.3%* (0.0-9.6)	4.5%* (0.0-10.8)	4.8%* (0.0-10.2)
Received service	14.3%* (0.0-30.1)	9.1%* (1.9-16.2)	6.1%* (0.0-12.4)	20.2%* (8.3-32.2)	4.5%* (0.0-9.6)
Did not need, did not receive service	80.8% (64.1-97.4)	87.7% (79.4-96.0)	89.6% (81.5-97.8)	75.3% (62.3-88.3)	90.8% (83.4-98.2)
Professional HIV Medication Adherence Support Services					
Needed, but did not receive service	2.2%* (0.0-6.5)	0.0%	1.9%* (0.0-4.8)	2.0%* (0.0-6.0)	1.3%* (0.0-3.8)
Received service	39.2% (20.3-58.0)	28.0% (15.9-40.1)	33.6% (18.9-48.4)	46.4%* (30.9-62.0)	30.0%* (15.5-44.4)
Did not need, did not receive service	58.7% (39.6-77.7)	72.0% (59.9-84.1)	64.5% (49.7-79.3)	51.6%* (35.8-67.3)	68.8% (54.2-83.3)

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[a] (95% CI)[b]	%[a] (95% CI)[b]	%[a] (95% CI)[b]	% [a] (95% CI) [b]	%[a] (95% CI)[b]
Domestic Violence Services					
Needed, but did not receive service	7.6%* (0.0-21.6)	1.7%* (0.0-5.0)	0.0%	1.7%* (0.0-5.0)	0.0%
Received service	0.0%	0.0%	2.1%* (0.0-6.3)	2.4%* (0.0-6.9)	3.6%* (0.0-8.5)
Did not need, did not receive service	92.4% (78.4-100.0)	98.3% (95.0-100.0)	97.9% (93.8-100.0)	96.0% (90.3-100.0)	96.4% (91.5-100.0)
TOTAL	**43**	**55**	**65**	**51**	**53**

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children. Note: Persons could report receiving or needing more than one service. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. a Stigma scores were measured with a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures four dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, and perceived public attitudes about people living with HIV. People were classified as having experienced high levels of HIV stigma if their score on the HIV stigma scale was in the top quartile for the 2015-2017 combined sample (score of ≥ 57.5). [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages. [c] Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.

Appendix Table 9.1. Prevention Services Use, by Cycle Year - Medical Monitoring Project, CA

	2015 %a (95% CI)b	2016 %a (95% CI)b	2017 %a (95% CI)b	2018 %a (95% CI)b	2019 %a (95% CI)b
One-on-one HIV/STD risk-reduction conversation with physician, nurse, or other health care worker					
Yes	58.8% (50.2-67.4)	44.4% (37.0-51.8)	48.8% (41.2-56.4)	48.6% (40.2-57.0)	57.8% (49.8-65.8)
No	41.2% (32.6-49.8)	55.6% (48.2-63.0)	51.2% (43.6-58.8)	51.4% (43.0-59.8)	42.2% (34.2-50.2)
One-on-one HIV/STD risk-reduction conversation with outreach worker, counselor, or prevention program worker					
Yes	28.7% (20.6-36.7)	28.9% (22.2-35.6)	23.4% (16.9-30.0)	30.7% (23.2-38.2)	26.8% (19.8-33.8)
No	71.3% (63.3-79.4)	71.1% (64.4-77.8)	76.6% (70.0-83.1)	69.3% (61.8-76.8)	73.2% (66.2-80.2)
Attended an organized HIV/STD risk-reduction session involving a small group of people					
Yes	12.4% (6.5-18.3)	9.1% (4.5-13.6)	9.1% (5.2-13.0)	14.0%* (8.6-19.4)	12.4%* (6.8-17.9)
No	87.6% (81.7-93.5)	90.9% (86.4-95.5)	90.9% (87.0-94.8)	86.0% (80.6-91.4)	87.6% (82.1-93.2)
Received free condoms					
Yes	53.6% (44.6-62.6)	48.5% (41.0-56.0)	47.3% (39.8-54.9)	47.0% (38.6-55.3)	44.2% (36.2-52.3)
No	46.4% (37.4-55.4)	51.5% (44.0-59.0)	52.7% (45.1-60.2)	53.0% (44.7-61.4)	55.8% (47.7-63.8)
TOTAL	176	221	229	192	218

Abbreviation: CI, confidence interval. Note: Persons could report receiving more than one prevention service. [a] Percentages are weighted percentages. [b] CIs incorporate weighted percentages.

Appendix Table 10.1. High HIV Stigma[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA

	2015 %[b] (95% CI)[c]	2016 %[b] (95% CI)[c]	2017 %[b] (95% CI)[c]	2018 %[b] (95% CI)[c]	2019 %[b] (95% CI)[c]
Gender					
Male	22.5% (13.9-31.2)	29.0% (21.2-36.9)	21.8% (15.0-28.6)	24.3% (16.7-31.8)	25.8% (18.1-33.5)
Female	23.0%* (6.9-39.1)	26.8%* (9.7-43.9)	30.5% (14.9-46.1)	23.0%* (7.6-38.4)	36.6%* (12.4-60.9)
Transgender[d]	0.0%	0.0%	21.7%* (0.0-60.5)	21.2%* (0.0-59.4)	0.0%
Sexual Orientation					
Lesbian or gay	20.4% (10.4-30.4)	20.7% (12.5-29.0)	18.7% (10.9-26.5)	23.2%* (13.5-32.8)	31.5% (21.6-41.4)
Heterosexual or straight	25.7% (11.7-39.7)	29.4% (16.3-42.6)	34.6% (21.7-47.4)	29.7%* (17.9-41.6)	26.3%* (11.1-41.5)
Bisexual	40.4%* (3.8-76.9)	53.3% (30.3-76.4)	21.2%* (3.2-39.1)	22.8%* (0.0-47.0)	17.7%* (0.0-36.2)
Other	0.0%	57.2%* (18.3-96.2)	27.5%* (0.0-58.1)	17.9%* (0.0-41.2)	0.0%
Race/Ethnicity					
American Indian/Alaska Native	---	21.9%* (0.0-64.6)	31.6%* (0.0-83.7)	41.9%* (0.0-100.0)	21.5%* (0.0-68.5)
Asian	100.0%*	51.0%* (1.8-100.0)	0.0%	5.8%* (0.0-25.1)	0.0%
Black/African American	20.0%* (2.6-37.4)	51.1% (32.6-69.5)	21.7%* (8.3-35.1)	25.8%* (9.4-42.3)	18.8%* (1.2-36.4)
Latinx[e]	21.1%* (8.0-34.1)	24.6% (13.0-36.3)	25.9% (16.0-35.8)	32.3%* (18.6-46.0)	24.1% (14.9-33.4)
Native Hawaiian/Other Pacific Islander	0.0%	---	100.0%*	---	0.0%
White	19.4%* (6.6-32.2)	25.9% (15.1-36.7)	19.1% (8.6-29.5)	15.3%* (7.2-23.5)	34.1%* (20.7-47.4)
Multiple races	42.1%* (13.9-70.4)	3.5%* (0.0-10.3)	59.4% (28.3-90.6)	39.0%* (7.1-71.0)	0.0%

Appendix Table 10.1. High HIV Stigma[a] by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA *(cont.)*

	2015	2016	2017	2018	2019
	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]	%[b] (95% CI)[c]
Age at Time of Interview (yr)					
18–29	4.2%* (0.0-13.6)	41.0% (17.0-65.0)	5.7%* (0.0-14.6)	37.6%* (0.0-77.9)	35.4%* (11.8-58.9)
30–39	44.2% (19.0-69.4)	28.9%* (10.4-47.4)	27.8%* (10.9-44.7)	38.6%* (17.2-60.1)	20.1%* (4.9-35.4)
40–49	17.7%* (1.3-34.0)	30.1% (15.9-44.3)	30.7% (16.2-45.2)	25.0%* (10.9-39.1)	34.5%* (14.2-54.8)
≥50	20.4% (11.1-29.8)	25.6% (15.6-35.7)	21.1% (13.1-29.1)	18.9%* (11.9-25.9)	24.4%* (15.2-33.6)
TOTAL	**43**	**55**	**65**	**51**	**53**

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. [a] Stigma scores were measured with a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures four dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, and perceived public attitudes about people living with HIV. People were classified as having experienced high levels of HIV stigma if their score on the HIV stigma scale was in the top quartile for the 2015-2017 combined sample (score of ≥ 57.5). [b] Percentages are weighted percentages. [c] CIs incorporate weighted percentages. [d] People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. [e] Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

MEDICAL MONITORING PROJECT